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ROLE OF MACROPHAGES IN MUSCLE TRANSFECTION WITH pDNA/PLURONIC 
FORMULATION 
Non-ionic amphiphilic block copolymers of poly(ethylene oxide) (PEO) and 
poly(propylene oxide) (PPO), Pluronics, arranged in a tri-block structure PEO-PPO-PEO, 
have raised a considerable interest in skeletal muscle Gene Therapy. Previous studies 
have demonstrated that co-administration of Pluronics with naked plasmid DNA (pDNA) 
by direct i.m. injection enhanced transgene expression not only in muscle but also in distal 
lymphoid organs (spleen and lymph nodes) and this response was strain-dependent; not 
observed in athymic (BALB/c nu/nu) mouse; suggesting a role of immune cells in gene 
transfer to skeletal muscles. Therefore, we first evaluated the role of inflammation and 
inflammatory cells, on muscle transfection. We showed that local inflammation in murine 
hind limb ischemia model (MHLIM) drastically increased DNA, RNA and transgene 
expression levels in muscles injected with pDNA/Pluronic. Ischemic muscles showed high 
number of GFP+ muscle fibers with GFP expression co-localized with desmin+ muscle 
fibers and CD11b+ macrophages (MØs). This suggested that MØs assist muscle 
transfection with pDNA/Pluronic. Moreover, adoptively transferred MØs were shown to 
pass the transgene to inflamed muscle cells. Hence, we developed an in vitro model of 
inflammation by co-culturing transfected MØs with myotubes (MTs) and used constitutive 
(cmv-luciferase) or muscle specific (desmin-luciferase) reporter gene expression to show 
that Pluronic P85 enhances the horizontal pDNA transfer from MØ to MTs. Systemic 
inflammation (MHLIM and peritonitis) also increased the transgene expression with 
pDNA/Pluronic but not pDNA alone. Second, we carried out an immunological profiling of 
adjuvant (P85/LPS/Alum) induced cellular recruitment and showed that P85 helps 
modulate the response towards MØs predominated recruitment. Moreover, the 
contribution of MØ predominance in assisting gene transfer after i.m. injection of 
x 
 
 
 
pDNA/P85 was reinforced by in vivo MØ depletion that resulted in near complete 
attenuation in gene expression to the level of naked pDNA alone. Finally, MØ recruitment 
response was harnessed to further increase muscle transfection by preinjecting P85 at 
the subsequent sites of pDNA/P85 injection resulting in improved muscle transfection. 
This dissertation study provides a key evidence about the role of MØs in assisting gene 
transfer in pDNA/Pluronic delivery approach. Altogether, we introduce Pluronics as simple 
and commercially available excipients to enhance gene transfer using pDNA/Pluronic 
admix compositions; are recognized pharmaceutical excipients in US and British 
Pharmacopoeia and therefore have great potential in human gene therapy clinical trials in 
healthy and disease pathologies that often involves inflammation. 
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CHAPTER 1 
1.1. Introduction 
DNA was first identified in 1869 by a Swiss Physiological chemist, Friedrich 
Miescher from nuclear isolates of white blood cells, as a molecule which was resistant to 
protease digestion, therefore was not protein so he called it “nuclein” which was later 
named “nucleic acid” and finally “deoxyribonucleic acid” or DNA (1). The 3-dimensional 
structure of DNA, was not known until 1953, when Watson and Crick made a ground 
breaking conclusion that 1) DNA exists in double helix, 2) the double helix is a right handed 
structure, 3) the strands run in antiparallel direction, and 4) the two strands are connected 
together by hydrogen bonding (2). Since the structure showed how the nucleotides in the 
opposite strands are paired (A-T and G-C), it helped enormously understand the genetic 
code of life and its applications in gene therapy and other fields.  
The concept of “Gene Therapy” was then proposed in 1960s and 1970s that 
DNA molecule encoding therapeutic protein has a great potential and can be used to 
replace defective genes in patients with genetic disorders. This lead to research focus on 
vectors to deliver genes and the first gene therapy clinical trial was approved in 1989. At 
present, a total of approx. 2000 clinical trials worldwide have been conducted until the end 
of 2015 for various diseases (http://www.wiley.com/legacy/wileychi/genmed/clinical/). The 
approaches for delivering genes in the clinical trials can be basically divided into two 
categories; viral gene delivery and non-viral gene delivery. Most of the clinical trials studies 
(~70%) have been conducted using viral vectors because of natural tropism whereby, 
viruses have inherent capacity to bypass various cellular barriers for transporting DNA into 
nucleus that results in very high transfection of various tissue/cell types. However, the viral 
vectors pose severe safety concerns due to their ability to generate strong immune 
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responses and the possibility of integration into host proto-oncogenes. Most notable being 
the death of a patient in USA in 1999 due to inflammation against modified adenovirus 
vector in phase-I clinical trial study conducted by University of Pennsylvania-Philadelphia 
(3-5). In another study conducted in France, out of 11 patients treated for X-linked SCID 
disease or bubble boy disease syndrome using retrovirus vector, 3 patients developed T- 
cell leukemia due to integration of virus downstream of a transcription factor, whose over 
expression resulted in T-cell lymphoblastic leukemia (6, 7). Similarly, one patient in 
England also developed T-cell leukemia when treated with similar retrovirus treatment. 
These events led to immediate halt of other gene therapy clinical trials worldwide using 
retroviruses for gene delivery purpose to X-SCID patients. Another patient in USA in 2007 
died of receiving an AAV vector for treatment of rheumatoid arthritis but the reason for her 
death has been under debate. 
On the other hand, most of the non-viral gene delivery platform (~ 23% of total 
worldwide clinical trials) utilizes plasmid DNA (pDNA) for therapeutic protein expression 
or DNA vaccination. The major benefit of using pDNA is its excellent safety profiles unlike 
viral gene delivery approaches and are discussed in detail in chapter 2. Direct injection of 
naked pDNA results in muscle transfection and reporter protein expression in vivo was 
serendipitously discovered in 1990s. Even now, naked pDNA injection is by far the most 
common method of non-viral gene delivery in clinical trials for 1) local or systemic 
therapeutic protein expression and 2) expression of antigen protein for DNA vaccination. 
However, this approach suffers a major drawback of low gene expression versus viral 
gene delivery which in contrast results in stable and high gene expression using some 
viruses. Not many advancements in the approach of naked pDNA delivery have been 
made so far that can help increase muscle transfection except electroporation mediated 
gene transfer (EGT). EGT employs high voltage electric pulses using electrodes to drive 
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pDNA across the muscle membranes but suffers a major drawback of inducing significant 
muscle damage and cannot be used in muscular dystrophies where the aim is the rescue 
already degenerating tissue.  
pDNA is a negatively charged macromolecule and cannot cross the cell 
membrane barrier which is why researchers tried to complex it with cationic lipids 
“Lipoplex” or cationic polymers “Polyplex” to make neutral nanoparticles to enhance its 
cellular uptake. This approach significantly enhanced the transfection of pDNA in vitro in 
various cell types but no such increase was observed when these complexes were 
injected directly into muscle. Rather, naked pDNA alone transfected muscles to higher 
levels than any lipoplex or polyplex used (8). Therefore, there is a need to understand the 
complex uptake of naked pDNA in the skeletal muscle so that the delivery approach can 
be improved. This would help open up new avenues for therapeutic application of naked 
pDNA especially in diseases where currently viral vectors are the only option as gene 
delivery vectors. 
One unique platform that enhance gene expression of pDNA in muscle are the 
Pluronic block copolymer. Pluronic block copolymers are non-ionic triblock structures that 
consist of hydrophilic Ethylene Oxide (EO) and hydrophobic Propylene Oxide (PO) blocks 
arranged in A-B-A structure, i.e. EOn-POy-EOn, where the length of EO and PO blocks vary 
in different types of pluronics. Pluronic belong to a category of non-ionic copolymers 
known by names poloxamers, Synperonics, CRL, SP. Pluronics have been categorized 
into families according to the arrangement as A-B-A (pluronic) and B-A-B (pluronic R). 
Every pluronic has a different hydrophilic-lipophilic balance (HLB) ratio depending upon 
the relative balance of EO and PO units and different critical micelle concentration (CMC). 
Accordingly, hydrophobicity of a pluronic is inversely correlated with the HLB value. 
Nomenclature of Pluronic uses letters F solid, P paste and L liquid followed by three or 
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two numeric digit. The last digit of the Pluronic name corresponds to percentage of 
ethylene oxide i.e. 8 means 80% of the EO and the first one or two corresponds to 
approximate molecular weight of PO when multiplied with a factor 300. e.g. F127, L61 etc. 
When coadministered with pDNA, these copolymers increase gene expression in orders 
of magnitude in DNA injected muscle.  Because these are non-ionic so unlike cationic 
lipids/polymers, they do not interact with pDNA, implying that condensation of pDNA in 
lipoplexes and polyplexes may be the reason for decrease in muscle transfection 
compared with naked pDNA alone. In addition to other advantages, pluronics also provide 
relatively safe formulations in comparison to cationic polymers and the toxic side effects 
of pluronics have been reported to be correlated to the lipophilicity of the copolymers and 
occur far beyond the concentration used for gene therapy. Notably, pluronics are 
mentioned in United States Pharmacopoeia as FDA approved excipients for drug-
formulations. 
Pluronics offer a very simple and cheap formulation for muscle transfection, 
and they have been studied extensively for drug and gene delivery (9). As an adjuvant, 
Pluronics have been widely used in protein formulations for vaccination purposes. 
Pluronics were shown to increase the systemic expansion of Dendritic Cell (DC) and local 
expansion of DC, macrophages and natural killer cell population.  Therefore, copolymer 
based muscle transfection in comparison to naked pDNA approach offers two great 
models to study the mechanism of muscle transfection. In our previous studies, we have 
observed that immune system plays a crucial role in muscle transfection and gene 
expression due to following observations: 1) when coadministered with pDNA, Pluronic 
P85 increased gene expression not only in injected muscle tissue but also in the distal 
lymphoid organs such as draining lymph nodes and spleen. 2)  The gene expression 
colocalized with CD11b+ APCs in muscle, lymph nodes and spleen and the proportion of 
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GFP+APCs increase upon coinjecting pDNA with P85. 3) Furthermore, we observed that 
increase in muscle gene expression in naked pDNA upon coadministering with P85 was 
strain-dependent and was not observed in athymic nude mice. All the observations 
suggested that block copolymer based gene delivery approach may employ immune 
system cells for increasing the gene expression in muscles. Therefore, in this dissertation 
study, we focused on the role of immune cells in block copolymer based muscle 
transfection for assisting gene/protein transfer to the skeletal muscle fibers using different 
in vivo and in vitro models. Specifically, chapter 1 introduces problem, hypothesis and 
specific aims of the thesis. Chapter 2 serves as an introductory basis on the role of 
inflammation (immune cells and inflammatory factors) on gene expression of non-viral 
gene delivery. Chapter 3 focuses on the role of inflammation (local and distal) and 
inflammatory cells on gene expression of naked pDNA alone and when coformulated with 
block copolymers (P85 and SP1017). Chapter 4 describes a rational approach to dissect 
the innate immune response to naked pDNA alone or when coformulated with block 
copolymers using peritoneal lavage and characterize and proves the role of specific cells 
(macrophages or MØ) in muscle transfection. Also, this chapter presents an engineering 
approach where MØs were recruited to the subsequent sites of pDNA injection to further 
increase the muscle transfection levels of pDNA/P85.  Finally, Chapter 5 focuses on the 
overall discussion, conclusion and future studies.
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CHAPTER 2 
REVIEW OF LITERATURE: ROLE OF INFLAMMATION IN GENE DELIVERY TO 
MUSCLE 
2.1. Gene delivery  
DNA delivery for therapeutics is a relatively new field of biotechnology in 
comparison to small molecule and proteins therapeutics. Specifically, genes can be 
delivered to target cells for therapeutic protein expression such as dystrophin in muscular 
dystrophy (1) or to express antigenic proteins for prophylactic or therapeutic vaccination 
response (2). DNA delivery is particularly a viable approach for substituting protein 
delivery in host tissue due to practical hurdles like short half-life, instability and high cost 
of manufacturing and immunogenicity of therapeutic proteins (3). 
2.1.1. An overview of viral and non-viral gene delivery 
As of January 2015, majority, ca.70% (n=1446) of the worldwide gene therapy 
clinical trials have been conducted using viral vectors and the second major ca. 23% 
(n=546) using non-viral vectors, mostly naked plasmid DNA (pDNA) 
(http://www.wiley.com/legacy/wileychi/genmed/clinical/). In lieu of obvious advantages 
offered by viral vectors, high immunogenicity (humoral and cellular immune response from 
high vector dose), complex delivery systems, inability of repeated administration of same 
serotype and high cost of production limits its application (4). On the contrary, non-viral 
gene delivery using naked pDNA, is preferred due to their ease and low cost of production, 
flexibility to customize, very stable at room temperature, low immunogenicity and most 
important being the ease of repeated administration. However, despite of all advantages, 
pDNA delivery is infamous for practical hurdles like inefficiency to transfect skeletal 
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muscles and transient increase in gene expression. Therefore, recent technological 
developments in non-viral gene delivery (physical, chemical and biological methods) has 
focused mainly on enhancing muscle transfection with naked pDNA to clinical 
meaningfulness. At the same time, all technological innovations added to the complexities 
and cost, to a moderate levels to otherwise simple pDNA delivery system. Nevertheless, 
in spite of all hurdles, naked pDNA is still preferred for gene delivery in human clinical 
trials. 
2.1.2. Bottlenecks of non-viral gene delivery 
Inflammation is a complex phenomenon and even at lower extents, it can have 
some negatively impacts on non–viral gene delivery. Specifically, inflammation can be 
actuated due to unmethylated CpG dinucleotides or CpG motifs of viral promoters in pDNA 
backbone, foreignness of chemical vectors (e.g. cationic lipid/polymer) and the 
invasiveness of physical delivery approach (e.g. electroporation). Notably, these events 
are at far lower levels than immune responses against viral vectors. Even though the local 
adjuvant effect, including release of pro-inflammatory factors and recruitment of 
inflammatory cells, are a prerequisite for an effective gene delivery for vaccination, these 
negatively affect transgene expression. For e.g. un-methylated CpG sequences in 
bacterially derived pDNA activates pro-inflammatory factor secretion (TNF-α, IL-12, IL-6, 
IFN-γ) resulting in premature silencing of gene expression (5). However,  the inhibitory 
effect on gene expression was reduced by using methylated pDNA or by using purified 
expression cassettes without CpG pDNA backbone (5). The exact mechanism of 
epigenetic silencing of the pDNA has not been elucidated yet, and use of hybrid promoters 
with partial or exclusively mammalian sequences have helped prolong gene expression 
(6). The transient gene expression can also be very tissue specific and dependent on cell 
turnover, which is why the gene expression in tumor tissue is very short lived (7, 8). 
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Moreover, inflammation response due to direct intra-muscular injection is unescapable. 
Therefore, it is imperative to understand and dissect its effects on naked DNA gene 
expression for unravelling the inhibitory responses and use it in the favor of stable gene 
expression. 
2.1.3. Focus of the review 
Because of inflammation being a complex response and there are known 
negative impacts of inflammatory signaling on gene expression, technological 
developments in gene delivery studies rationalize increased gene transfer to the 
technology itself keeping the effects of inflammation on the side track. These observations 
along with our experience where inflammatory cells help gene expression, prompted us 
to bridge the knowledge gap between the positive influence of inflammation on 
transcriptional activation or gene transfer to the skeletal muscles. Therefore, we compiled 
reports on each successful gene delivery approach using naked pDNA with/without a 
vector and their effects alone or in combination on inflammation and transgene 
expression. 
2.2. Inflammation and non-viral gene delivery. 
We believe that inflammation, can be utilized as a friend than a foe to assist 
gene expression for multiple reasons. Firstly, most of the pDNA vectors carry a constitutive 
cmv-promoter, composed of multiple nuclear factor ĸB (NF-ĸB) binding sites, which is 
highly responsive to NF-ĸB phosphorylation and transcriptional activation during 
inflammatory responses (9). Secondly, basal NF-ĸB levels in cell cytoplasm are enough 
to drive pDNA import from cytoplasm to nucleus and this response can further be 
enhanced in inflammation (10). Thirdly, cellular infiltrates during inflammation are majorly 
composed of highly phagocytic myeloid cells such as neutrophils, monocytes, 
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macrophages which can uptake pDNA and express reporter genes thus representing as 
an additional reservoir to muscle fibers resulting in increased total gene expression (11, 
12). Finally, monocytes and macrophages can also assist in the transfer of genes/proteins 
to the neighboring cells thus increasing the transfection efficiency (discussed later). 
2.2.1. Mechanism of gene transfer in skeletal muscle 
Muscle transfection by direct i.m. injection of naked pDNA was a serendipitous 
discovery in 1990 by John Wolff and coworkers at University of Wisconsin-Madison (13). 
The results were striking and proposed mechanisms suggested a pDNA transfer through 
membrane disruptions caused by needle penetration but no histological evidence were 
provided to support the conclusions. A decade later, highly efficient liver transfection by 
large volume (2.5 ml) hydrodynamic tail vein injection of naked pDNA was also reported 
(14).  It was suggested that a pDNA uptake in muscle and in liver is mediated through a 
specific receptor, which can be inhibited upon co-delivering polyanionic molecules (15). 
Specifically, pDNA uptake was inhibited upon co-administration of heparin, polyglutamic 
acid, polyinosinic acid, dextran sulphate but not by all polyanionic molecules e.g. 
polycytidilic acid and chondroitin sulphate. This suggested a role of scavenger receptors 
in pDNA uptake in a charge and/or structure dependent manner (16). A successful pDNA 
uptake and gene expression was found to be a slow mechanism that required 
accumulation of pDNA molecules in muscles in first 4 h (15). With no conclusive 
mechanism of pDNA uptake the research focus of naked pDNA-based gene delivery was 
diverted towards the technological advancements (physical chemical or biological vectors) 
to enhance the muscle gene expression levels which alter the mechanism of pDNA uptake 
as discussed later.  
2.2.2. Parameters affecting gene expression in skeletal muscle 
11 
 
 
11 
Immediately after direct i.m. injection of naked pDNA was proposed, 
parameters affecting the gene expressions were studied for many years with a hope to 
further optimize and increase the levels of gene expression. These include the effect of 
needle type, injection speed, direction of injection (perpendicular or parallel to muscle 
fibers), injection volume, osmotic gradient of injection fluid, type of solute, type of muscle 
tissue, physiologic condition of the muscle, age and sex of the animals, pre-injection 
(hypertonic sucrose solution, bupivacaine, barium chloride), promoter type, size and form 
of DNA (linear, open or supercoiled) (17-23). 
2.3. Effect of inflammation on gene expression of naked pDNA 
Regardless of the painstaking efforts, no significant improvements were made 
probably because the serendipitous observation of muscle transfection upon direct 
injection of naked pDNA gave a quick lead to gene therapy field over complex skeletal 
muscle biology which was not understood at that time. Although, skeletal muscles were 
known for a mysterious regenerative potential unlike any other tissue the beneficial role of 
inflammatory cells in helping muscle regeneration was not known until lately and 
discussed below. Similar muscle regeneration and inflammatory response can also follow 
after physical injury caused by direct i.m. injection of pDNA and the unmethylated CpG 
sequences in the pDNA backbone (24). As discussed below, we believe that inflammatory 
response and muscle transfection can be mutually inclusive and can enhance gene 
expression levels. 
2.3.1. Direct injection of naked pDNA in muscle 
Many past studies related to naked pDNA injection in muscle have reported 
overlapping observations of muscle inflammation dependent increase in transgene 
expression not only in skeletal muscle but also in the distal lymphoid organs. The earliest 
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study was reported by Takeshita et al when inflammation resulted in an order magnitude 
increase in gene expression in ipsilateral ischemic muscles compared to intact 
contralateral muscles upon direct i.m. injection of pDNA (25). However, the possible 
effects of inflammatory cells in contributing to muscle gene expression were not 
discussed. The first indirect role of inflammatory cells in contributing to the gene 
expression in healthy muscle or draining lymphatic tissues was reported by Torres et al. 
The authors showed that surgical removal of TA muscle shortly after pDNA administration 
(10 min) did not abrogate the Ag specific immune response suggesting that the genes in 
the muscles were probably taken up and expressed by the draining APCs in the distal 
organs such as lymph nodes or spleen to induce protective immunity (26). Later, many 
follow up studies reported transgene expression in dendritic cells and/or MØ in the 
draining lymph nodes and spleen after administration of pDNA by scarification (27), i.m. 
injection (12) and intradermal injections (28). The results were further confirmed by tissue 
distribution studies of fluorescently labeled pDNA in TA muscle by Dupuis et al who 
showed that majority of the Rh-pDNA 24 h after injection co-localized with CD11b+ APCs 
in muscle and draining lymph nodes suggesting that earlier observations on colocalization 
of reporter protein in APCs was not exclusively because of protein uptake from the 
transfected muscles but also by reporter protein expression due to pDNA uptake  (11). 
Interestingly, Gaymalov et al showed that co-administration of synthetic adjuvants such 
as amphiphilic block copolymers with pDNA substantially increased gene expression in 
CD11b+ APCs in injected muscles, draining lymph nodes and spleen compared to naked 
pDNA alone which suggested an additive effect of gene expression cause by artificial APC 
recruitment response by copolymers (29). All-together, a body of evidence exists for the 
involvement of immune cells in transgene expression in muscle and distal organs which 
can be maneuvered by use of additional adjuvants.  
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2.3.2. Rapid intra vascular injection in muscle 
Upon direct i.m. injection, the diffusion of pDNA in skeletal muscle is limited 
because pDNA has to cross the extracellular matrix to reach each muscle fiber. Since 
muscles have a high density of capillaries that reach out to each muscle fiber, the diffusion 
barrier can be avoided by intra vascular delivery which is also clinically attractive approach 
for delivering the pDNA to different muscles. In 1998, Budker et al for the first time showed 
a successful arterial gene delivery approach in small animals (rats) using large volume 
(10ml) injection and outflow of liquid blocked that resulted in 40 times increase in muscle 
transfection compared to i.m. injection (30). Later, another successful delivery in large 
animals (rhesus monkeys) was reported by Zhang et al. who delivered 150 ml pDNA 
solution using catheters via femoral artery with a simultaneous tourniquet to stop the 
outflow of liquid resulting in transfection of up to 40% of the muscle fibers (31). 
Vascular delivery approach allowed transgene expression throughout the 
muscle in comparison to local expression around needle track upon direct i.m. injection 
and it reproduced in both small and large animals. However, other studies showed an 
increase in serum creatine kinase, minor swelling and accumulation of neutrophils 
(CD43+) and macrophages (ED1+ and ED2+) in muscles following tourniquet approach 
confirming an inflammatory response due to high volume liquid injection in vasculature 
(32, 33). We believe, that these immune cells can also contribute to the total gene 
expression but these studies didn’t analyze any co-localization of transgene expression 
with macrophage or neutrophil markers. 
2.3.3. CpG sequences 
Upon phosphorylation of inhibitor kappaB protein, active NF-kB transcription 
factor enters nucleus and binds unmethylated CpG motifs of TATA promoter sequence for 
transcriptional activation of genes (34-36). Therefore, most commercially available pDNA 
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vectors are designed with viral promoters (human cytomegalovirus [CMV] and rous 
sarcoma virus [RSV]) that carry unmethylated CpG sequences for driving a constitutive 
expression of reporter transgenes in various cell and tissue types (37). During 
inflammation, activation of various signaling pathways results in NF-kB upregulation which 
can enhance reporter gene expression (9, 34-36). Sriadhibatla et al. showed that Pluronic 
enhanced gene expression in stably and transiently transfected fibroblasts was due to 
activation of stress signaling (upregulated hsp-68) resulting in enhanced NF-kB and AP-1 
levels (38). The CpG driven gene expression is a very specific response and methylation 
and unmethylation of CpG in rous sarcoma virus promoter was shown to decrease and 
increase transgene expression respectively (39).  
2.4. Effect of inflammation on chemical gene delivery 
Naked pDNA alone has a short plasma half-life (< 5min), therefore i.v. injection 
for lung/liver delivery requires encapsulation with cationic non-viral vectors. Therefore, 
calcium phosphate, cationic lipids (most popular), cationic polymers and cationic amino 
acids have been utilized to neutralize the charge, condense the pDNA, protect from 
nuclease degradation and increase the cellular uptake via endocytosis. Nevertheless, 
surface chemistries and combinations of non-viral vectors can activate immune responses 
resulting in inflammation as discussed below. 
For instance, pDNA without CpG motif and cationic liposome alone were 
shown not to activate inflammatory pathways in MØs as expected. However, complexes 
of both triggered release of inflammatory cytokines by MØs in vitro suggesting a CpG 
independent inflammation (40). Another study suggested that inflammatory cytokines 
induce epigenetic silencing of pDNA resulting in transient gene expression. Therefore, for 
a successful gene delivery, DNA formulations need to be specifically designed to keep the 
inflammation at the lowest. Kako et al. showed that cationic lipid carrier and unmethylated 
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CpG motifs of pDNA cause systemic inflammation upon i.v. injection of lipoplex resulting 
in high serum TNF-α levels and initial increase in gene expression in various organs 
compared to pDNA alone injections (41). The effects of inflammation-dependent increase 
in gene expression were confirmed when depletion of MØ by clodronate and inhibition of 
inflammation by dexamethasone decreased the initial gene expression in liver, spleen and 
lungs (41). However, dexamethasone treatment resulted in prolonged gene expression. 
This was likely due to effects of lower systemic inflammation and TNF-α levels that 
resulted in lower epigenetic silencing of pDNA. This suggests that MØ are closely 
associated with CpG induced TNF-α secretion. Similar responses were observed on liver 
gene expression (42). Specifically, gene expression after direct RII infusion (retrograde 
intrabiliary infusion) of PEI-pDNA, chitosan/pDNA and naked pDNA alone increased in 
MØ depleted mice than healthy mice from day 3 until day 15 (42) again suggesting that 
MØ induced inflammatory responses cause epigenetic silencing. Therefore, MØ induced 
inflammation plays a central role behind the transient gene expression and also provides 
an evidence for enhancing the initial gene expression. 
2.5. Effect of inflammation on physical gene delivery 
Electroporation mediated gene transfer (EGT) is the most promising technique 
of muscle transfection using naked pDNA. The procedure involves electrophoretic 
movement of naked pDNA across the transiently generated aqueous cell membrane pores 
in muscle. The technique was introduced as early as 1998, but the physiological and 
histological effects of electric pulses on muscle tissue had not been studied or/and 
reported in detail until lately (43, 44). The procedure induces local inflammation and 
massive recruitment of APCs depending on the pulse strength, pulse duration and 
distance of electrodes. Importantly, pulse voltages directly correlate with the levels of 
muscle transfection and relatively stronger electric pulses (voltages from as low as 
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100v/0.5cm to as high as 2000V/0.5cm) can increase the gene expression by 2-3 orders 
of magnitude along with unavoidable inflammation response in muscle (45, 46). 
Apparently, inflammation benefits the efficacy of otherwise non immunogenic pDNA 
vaccines mostly due to increased antigen processing and presentation provided by 
additional inflammatory cells (44, 47). On the downside, EGT results in ~80% decrease in 
muscle torque and contractility immediately after the procedure due to inflammation. 
Therefore, physiological assessments suggested lowering the voltages to at least 75V/cm 
along with pre-injection of hyaluronidase for minimal muscle damage with relatively higher 
gene expression (44, 48).  
So far, not many studies except few have studied in detail the contribution of 
transgene expression by inflammatory APCs or mononuclear cells in addition to 
transfected skeletal muscle fibers.  Gronevik et al showed that the number of transfected 
APCs per muscle after naked pDNA injection increased from 72±12 and 35±12 in soleus 
and quadriceps respectively to 447±95 and 499±11 due to EGT procedure (49), or  6-fold 
and 14-fold increase in GFP+ mononuclear cells in rats and mice respectively (49). 
Therefore, it implies that APCs can provide an additional reservoir for gene expression in 
the pDNA injected muscle and relatively stronger electric pulses should recruit higher 
number of these inflammatory cells resulting in higher additive effect in transgene 
expression. Similar observations were reported by others when longer (400µs instead of 
200 µs) and stronger (200 V/cm instead of 50 or 100 V/cm) electric pulses recruited APCs 
to a higher and lower levels respectively (50). Moreover, the gene expression of IgG2b in 
the initial weeks (1-3 weeks) was higher after long pulse (LP) EGT compared to short 
pulse (SP) EGT probably because of higher proportion of initial gene expression in cellular 
infiltrate along with muscle tissue. Later, at 4-12 weeks, once the inflammation was 
resolved, gene expression profiles of SP-EGT and LP-EGT flipped suggesting that high 
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inflammation after LP damaged the tissue of transfected muscle fibers what lead to a 
decrease in net gene expression at later time points  (50). In another study, muscle gene 
expression of cmv promoter-endothelial nitric oxide synthase showed a linear increase 
upon i.m. injection of pDNA with EGT on day 0, 3 and 7 post ischemia surgery compared 
to intact muscles  (51). Such an increase can be explained by the additive effect of gene 
expression by increasing recruitment of local inflammatory cells in muscle due to ischemia 
surgery. 
2.6. Effect of inflammation on combination delivery. 
Since alternative approaches for pDNA delivery employ different mechanisms 
of pDNA transfer across cell membranes, one would expect a synergistic or additive 
response of combining two separate approaches on transgene expression levels. 
2.6.1. EGT and CpG motifs 
EGT can enhance gene expression of naked pDNA independent of CpG 
sequences. However, insertion of NF-kB binding sequences upstream of promoter should 
be able to assist the pDNA transfer and gene expression due to the reasons discussed 
above. Mahindhoratep et al proved this concept by which, addition of NK-kB consensus 
sequences resulted in increased muscle transfection both with and without EGT (9). The 
results suggested that basal NF-kB levels are sufficient for enhanced pDNA import 
resulting in trans-gene expression of naked pDNA alone. However, additive effect of NF-
kB binding sequences and EGT on gene expression was also observed (9). 
2.6.2. EGT and hyaluronidase pre-injection 
Conceptually, enhanced intramuscular distribution of pDNA may result in 
enhanced electro transfer of DNA. This can be achieved by pretreatment of muscle with 
hyaluronidase (HYAse) that catalyzes the hydrolysis of hyaluronic acid, a major 
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component of extracellular matrix (ECM), leading to temporary decrease in viscosity of 
connective tissue and, therefore enhancing diffusion of fluids upon subsequent pDNA 
injection. To support this phenomena, Mennuni et al reported 5 and 17-24 times increase 
in muscle transfection in mice and rabbits respectively using different reporter protein 
expression constructs upon pretreatment with HYAse 1-4 h before EGT (52). It was 
discussed in many subsequent reports that HYAse pretreatment helps reducing the 
voltages of EGT but keep similar transfecting efficiencies with comparatively lower tissue 
damaging effect than high voltage EGT alone (48, 52, 53). However, the inflammatory 
effects of HYAse treatment had not been studied or discussed in detail until recently (54).  
A recent report confirmed that HYAse contribute to the local inflammatory effects of EGT 
in the initial 2 weeks. Specifically, HYAse amplified the inflammatory cell recruitment 
(F4/80+, CD11c+ and MHC-II+ cells) between before and after EGT resulting in enhanced 
early secretion of IL-1β, IL-6 and TNF-α cytokines (54). However, as discussed above, it 
has been shown that inflammatory cells directly contribute to transgene expression in 
healthy and ischemia mice (49, 51).  
2.6.3. EGT and block copolymers 
Non-ionic block copolymers are excellent polymers for gene and protein 
therapeutics (55). For gene delivery, coadministration of copolymers with naked pDNA 
(pDNA/copolymer) increases transgene expression in both muscle and distal lymphoid 
organs (29). Hunter et al showed that more hydrophobic, high molecular weight block 
copolymers were more active adjuvants for raising antibody responses than hydrophilic 
polymers (56, 57). Similarly, more hydrophobic block copolymers like L61 were also more 
active in enhancing muscle gene expression of naked pDNA than relatively hydrophilic 
polymers such as P85 or F127 (29). Hydrophobicity, has also been associated with the 
danger signals that results in APC recruitment and immune system activation which may 
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explain why the above explained response in protein and gene delivery were observed by 
relatively more hydrophobic Pluronics. Moreover, adjuvant response of Pluronic L61 was 
harnessed to recruit APCs to the subsequent site of EGT resulting in an order of 
magnitude increase in muscle gene expression compared to pDNA/L61 or pDNA and EGT 
performed at the same time. In another study, formulation of naked pDNA with SP1017; a 
mixture of relatively hydrophobic L61 (0.25% w/v) and relatively hydrophilic F127 (2% w/v), 
was shown to significantly increase EGT of naked pDNA alone to muscles from day 6 to 
day 30 (58). These observations suggested an overlap of inflammatory responses with 
the muscle transfection. 
On the other hand, hydrophilic copolymers have membrane stabilization and 
sealing properties as described elsewhere (59, 60), and hence can also be used to reduce 
muscle damaging effects or necrosis after electrical injuries due to EGT. This effect was 
confirmed when muscle damage quantified as a measure of serum creatine 
phosphokinase after EGT procedure was reduced using poloxamer 188 (HLB 29) (50). 
Similarly, high dose irradiation (upto 40-80Gy) lead to extensive cell membrane damage 
and acute cell necrosis, which was significantly improved by poloxamer 188 treatment 
(60).  
Non-ionic tri-block copolymers or Pluronics (EOx-POy-EOx) have characteristic 
central hydrophobic poly-propylene oxide (PO)y block flanked by relatively hydrophilic 
poly-ethylene oxide (EO)x blocks. The relative length of each block dictates the hydrophilic 
lipophilic balance (HLB) which further affects the physical and functional properties of the 
triblock. For e.g. Pluronics with lowest HLB have highest hydrophobicity, highest adjuvant 
effects and highest muscle transfection and vice versa (29, 61, 62).  
2.6.4. EGT and anionic polymers/lipids 
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 Relatively recently it was shown that coadministration of anionic, but not cationic 
or non-ionic lipids enhances the electroporation mediated drug transport across the cell 
membranes (63). This concept was leveraged by Nicole et al. to show that poly-glutamate, 
an anionic polymer, can enhance the transfer of pDNA during EGT (64). It was suggested 
that anionic molecules provide templates to neutralize the electroporation-induced 
processes that otherwise deactivate pDNA. Similarly, coadminstration of non-coding DNA 
aka “stuff DNA” which is stuffed into or mixed with coding pDNA was also shown to 
enhance the EGT gene transfer up to 21 times (65). The authors discussed that 
neutralization of positively charged components after electrical pulses offers competitive 
protection to coding pDNA resulting in enhanced gene expression.  However, the role of 
inflammatory effects of anionic molecules was not discussed herein.  
2.6.5. Block copolymers and inflammation 
 Block copolymer adjuvants enhance gene expression of naked pDNA in 
muscle in a dose dependent and HLB dependent manner resulting in a typical bell-shaped 
curve (29). It was recently shown that combination of inflammation and block copolymers 
show synergistic effect on the levels of muscle transfection. Local and distal inflammation 
drastically enhanced the gene expression of pDNA formulated with P85 or SP1017 in mice 
(Chapter 3). There was a substantial gene expression in CD11b+ cells in ischemic muscle 
compared to intact healthy muscles and the role of macrophages in enhancing the muscle 
transfection was studied (Chapter 3) and discussed below. 
2.6.6. Ultrasound and block copolymers 
Ultra sound is a very safe and widely used in clinical practice, which offers an 
attractive option for gene delivery. Studies have shown that ultra sound alone or in 
combination with microbubbles contrast agents help increase the cell membrane 
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permeability to pDNA (66). In principle, ultra sound helps pDNA transfer across the cell 
membranes via transient pores made by the constriction and swelling of gases from the 
micro bubbles (cavitation) around the skeletal muscles, therefore one may expect a higher 
gene expression in inflamed muscles due to transfection of local inflammatory cells. 
Danialou et al confirmed this by showing 3 times increase in transfected muscle fibers and 
22 times increase in total Lac Z protein in ultra sound mediated/microbubble gene transfer 
only during local inflammation in muscular dystrophy (mdx/mdx mice) and not healthy 
muscles (67). Moreover, combining Pluronic block copolymers (P85 but not F127 and L61) 
with ultrasound (without additional microbubble vectors) also increased gene expression 
but marginally (68). These effects may not be explained by the adjuvant effects of P85 
because L61 is more hydrophobic and more potent adjuvant. Also, there was no use of 
microbubbles as in earlier case. Therefore additive effects of both P85 and ultrasound 
may result in the observed effects.  
2.6.7. Pre-injection 
Muscles undergoing tissue damage and regeneration show enhanced muscle 
transfection of naked pDNA than intact muscles (21). For example, muscles pre-injected 
with barium chloride transfect to ~ 10 times higher levels than undamaged muscles (21). 
Similarly, snake venom (cardiotoxin) injection 5-11 days before pDNA injection also 
triggered similar increase in muscle transfection than uninjured muscles (23). These 
studies were conducted in late 1990s when the skeletal muscle biology was not completely 
understood.  Since MØs are constantly present in muscle and help regeneration, therefore 
they can also uptake and express reporter genes, which would increase the overall muscle 
gene expression. We have shown recently a similar effect when block copolymers 
assisted muscle transfection by guiding pDNA transfer from MØs to adjacent muscle cells 
(Chapter 3).  Therefore, we further engineered an improved muscle transfection approach 
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by pre-injection scheme. Specifically, MØs were recruited by block copolymer pre-injection 
to the site of subsequent pDNA/P85 injection to show a further increase muscle 
transfection (Chapter 4). Similarly as discussed above, pre-injection of block copolymer 
adjuvant 1 h before EGT of pDNA also increased muscle gene expression suggesting the 
role of inflammatory cells in facilitating muscle gene expression (69). 
Overall, all discussed factors suggests a more complex scenario of pDNA 
transfer across muscle membranes than just an electrophoretic movement of pDNA 
across the destabilized cell membranes as in EGT. Not if all, but non-electrical factors 
such as inflammation or inflammatory cells, DNA (CpG etc), DNA formulation, definitely 
affect gene expression in each case discussed above and have been discussed 
elsewhere in detail (70).  
2.7. Cell mediated in situ gene delivery 
Cell-to-cell communication among mammalian cells is analogous to commonly 
known “Quorum sensing” in prokaryotes. In recent years the prevailing view that 
eukaryotic cells are restrained from communicating and exchanging genetic information 
has been challenged (71). Mammalian cells have shown to have a one or a two way cell-
to-cell communication that operates through exosomes, microvesicles and tunneling or 
membrane nanotube structures (71-74). This structures carry and transfer a range of 
nucleic acids and proteins to other cell types (72, 74-76). Haney et al recently 
demonstrated that MØs transfected with GFP-DNA or catalase expressing DNA can travel 
across BBB, deliver DNA via secreted exosomes to adjacent cells resulting in GFP 
expression in brain parenchyma or reduced brain inflammation respectively in murine 
model of Parkinson disease (76). Thus, one can speculate that upon direct i.m. injection 
of pDNA, the tissue resident MØs can uptake and transfer the DNA via in situ horizontal 
gene transfer to other immune cells or adjacent host cell and express the transgenes. 
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The above mentioned approach can offer a practical advantage over existing 
cell based therapies which utilize the natural ability of circulatory cells for their ability to 
home to the sites of inflammation for drug/gene delivery (76-78). These approaches 
involve cumbersome ex vivo manipulation of cells before adoptive transfer which requires 
technically complex preparation, characterization of cells and the risk of contamination. 
Therefore, an in situ drug/gene delivery approach via host cells will offer a simpler and 
safer therapeutic option. 
2.7.1. MØs/Monocytes in skeletal muscle injury and gene delivery. 
MØs and their precursor cells, monocytes (MOs) play a central role in first line 
of defense and at the site of injury or inflammation. MØs are professional phagocytic cells 
that encounter pathogen and help antigen, processing and presentation to other immune 
cells for the resolution of infection. Specifically, bone marrow derived MOs constantly 
patrol in the circulation for the search of inflammation (79). After chemotaxis and 
extravasation towards the sites of infection, MOs mature into MØs while they help resolve 
infection and switch from pro-inflammatory type (M1-MØs) to anti-inflammatory type (M2-
MØs) to assist tissue damage, repair and then undergo apoptosis, drain into lymphatics 
as dendritic cells/macrophages or stay in the host tissue as resident MØs (79). During 
resolution of infection, MØs secrete cytokines to recruit T cells in the vicinity where they 
further assess the level of local inflammation by direct contact with MØs or in a “bystander 
effect” with/without any cell-to-cell contact and then respond by secreting factors that 
further initiates a concerted events of innate immune cell recruitment response including 
MØs as explained above. Because of their ability to enter any type of tissue, MØs have 
been used as “Trojan Horses” to deliver drugs across blood brain barrier, hypoxic regions 
or tumors, site of inflammation in joints or muscle etc. (76, 78, 80).  
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Skeletal muscle tissue has been long known for its unique regeneration 
potential unlike other tissues. Though, much interest had focused on the role of stem cells 
in muscle regeneration, the innate immune response determined the extent to which 
regeneration occurs (81). Later, Bone marrow transplant studies identified that 
hematopoietic stem cell intermediates with Mac1+Gr1+ myeloid cells/MØ phenotype (82-
85) or  Mac1+ cells Sca-1+/c-Kit+ (86) phenotype assist muscle regeneration through  MØ-
to-muscle cell fusion. This response was confirmed when, injured skeletal muscles failed 
to regenerate in MØ depleted mice (87). Therefore, MØs have gained particular interest 
for responding to tissue insult, persistence until resolution of muscle damage and 
protective effects on muscle membranes by cell-to-cell contact dependent manner (87, 
88). Similar effects of MØs were also shown in other tissues like liver, intestines and brain 
as explained elsewhere (89-92).  
Fusogenic response of MØs has also been seen elsewhere when multiple MØs 
fuse together to form Langhans giant cells with <20 nuclei arranged in circular peripheral 
arrangement or foreign body giant cells with >20 nuclei arranged in irregular arrangement. 
These giants cells are observed around the implanted biomaterials to form a avascular 
capsules which can lead to failure of implants (93). It was suggested that when MØs 
adhere to a surface, which is too large to be degraded effectively via phagocytosis, they 
become fusogenic (94, 95).  
2.7.2. MØs help gene transfer upon co-administration of block copolymers and 
pDNA.  
Upon direct injection of naked pDNA in muscle, APCs infiltrate the tissue, 
uptake the pDNA and express the transgenes in muscle, draining lymph nodes and spleen 
(12, 26). Pluronic block copolymers, widely studied for their adjuvant activity for both 
protein (57, 61) and DNA delivery (29, 96), have been shown to significantly enhance the 
25 
 
 
25 
process and increase the gene expression not only in DNA injected muscles but also in 
draining lymph nodes and spleen to upto an order or few orders of magnitude respectively 
(29). Notably, all the effects of copolymer induced increase in gene expression were 
strain-dependent with no effects in athymic nude mice suggesting that T cells were 
responsible for APC recruitment and increase in transgene expression (96). Similar T-cell 
dependent inflammation response “Bystander effect” to poly(ethylene oxide) prosthetic 
implants was observed in immunocompetent and  not in immunedeficient (athymic) strains 
of mice as explained by Sandhu et al (97).  
We have studied in detail the effects of APC recruitment on transgene 
expression upon i.m. injection of naked pDNA alone and when co-formulated with block 
copolymers (Chapter 3, 4). In particular, block copolymers drastically enhance and modify 
the cellular recruitment response towards MØ predominated response as opposed to 
other adjuvants (alum and LPS). The copolymers then selectively stimulate the gene 
transfer from pDNA transfected MØs to adjacent muscle cells resulting in muscle specific 
increase in gene expression in in vitro co-culture (Chapter 3). The specificity of MØ 
dependent muscle transfection was confirmed by reversal of copolymer enhanced gene 
expression to the levels of naked pDNA alone by in vivo depletion of MØs by clodronate-
liposome (Chapter 4). As expected, the transgene expression by pDNA/P85 further 
increased in presence of local inflammation in muscle suggesting that MØs and block 
copolymers are mutually inclusive for copolymer based muscle transfection approach. 
Significant but marginal increase in gene expression with naked pDNA alone was also 
observed in presence of inflammation. This knowledge was further utilized in engineering 
the MØ recruitment to the subsequent site of DNA injection to further increase the muscle 
gene expression of pDNA/copolymer formulation (Chapter 4). Therefore, we propose an 
in situ gene delivery approach using Pluronics that leverages help from immune cells 
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specifically MØs to deliver genes to adjacent cells, in this case skeletal muscles as shown 
in Fig. 1. Notably, resident MØs are not present in muscle parenchyma but in the 
epimysium/perimysium where they initiate and orchestrate the inflammatory response 
after a muscle injury (98, 99). 
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Figure 2.1. Block copolymer induced MØs recruitment response in muscle upon direct i.m. 
injection. A physical intervention (direct i.m. injection of naked pDNA alone or coformulated with 
Pluronic P85, CpG in pDNA backbone) can stimulate resident MØs present in the periphery of 
muscles epimysium/perimysium (98, 99) to start a T cell dependent or independent MØ recruitment 
response in muscle. After extravasating in the muscle upon pDNA/p85 injection, T cells in the 
vicinity of stressed resident MØs may show a “bystander effect’ by sensing local inflammation and 
secrete additional factors that recruits additional inflammatory cells including MOs. In contrast to 
naked pDNA alone, block copolymers helps enhance the cellular recruitment response 
predominated by MOs. As discussed in chapter 3, P85 can enhance pDNA transfer and gene 
expression in MØs and also enhance the horizontal transfer of pDNA from MØs to muscle cells. In 
a time dependent manner, transfected MØs may undergo apoptosis, mature into resident MØs or 
drain to the distal lymphatic organs. Since pDNA/P85 recruits massive number of MOs, more pDNA 
transfected MOs will drain to the lymphatics resulting in enhanced transgene expression in the 
draining lymph nodes and spleen. 
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Similar to Pluronics other non-ionic polymers have also shown up to 10-fold 
enhancement of transgene expression over naked pDNA alone (100).  We believe that 
block copolymers help MØs to fuse with muscle cells during muscle regeneration as 
explained above by excluding water molecules from the MØ-to-muscle cell contacts 
resulting in enhanced gene transfer (Fig. 2). A similar synthetic approach of stimulating 
cell-to-cell fusion can be explained by PEG based cell-to-cell fusion in hybridoma 
technology for creating somatic cell hybrids. Since the triblock structures of Pluronics have 
PEG on the flanking ends, depending on the length of PEG block, different copolymers 
can increase the natural MØ-to-muscle cell fusion response to different extents. 
MØ-to-muscle cell fusion mechanism can also assist gene transfer response 
after naked pDNA alone injections in muscles undergoing inflammation and regeneration 
after hind limb ischemia, preinjection with cardiotoxin, barium chloride or bupivacaine.  
 
29 
 
 
29 
 
Figure 2.2.  Proposed model of horizontal gene transfer from MØ to muscle cell fusion upon 
i.m. injection with pDNA/P85. Since, MØs are recruited to the sites of naked pDNA injections as 
a result of physiological insult caused by needle injury, these MØs phagocytose extracellular naked 
pDNA and then fuse (very low frequency <0.1%) with the existing muscles as a part of regeneration 
process thus, delivering pDNA into otherwise hard to transfect skeletal muscles. However, Pluronic 
can enhance the horizontal gene transfer from the transfected MØs to muscle fibers by assisting 
cell to cell fusion. The latter step is similar to polyethylene glycol (PEG) mediated cell-to-cell fusion, 
in which it involves exclusion of water molecules between lipid bilayers and changing the orientation 
of molecular dipoles that results in membrane fusion as in somatic cell hybrid technology (101-
104). Since Pluronics contain PEG as well as polypropylene glycol chains capable of incorporating 
into lipid membranes (105), we believe that they can enhance the MØs to muscle cell fusion events 
eventually delivering pDNA to muscle fibers (horizontal gene transfer) and increasing transfection 
and gene expression both in healthy and inflamed muscles. 
30 
 
 
30 
2.8. Overall conclusions. 
New approaches in non-viral gene delivery are developing at a fast scale, with 
relatively less understanding in gene transfer mechanism. With a better knowledge of 
skeletal muscle biology at present, there is a need for research focus towards mechanistic 
of gene transfer in vivo upon direct i.m. injection so that key bottlenecks and the limitations 
of non-viral gene delivery can be overpowered. To this end, development of in vitro models 
relevant to in vivo gene transfer upon direct injection is also very critical. For e.g. 3D 
muscle models have been shown to have more active endocytosis compared to in 2 D 
cultures which may provide more insights into pDNA uptake in otherwise hard to transfect 
2D muscle models in vitro. Additionally, block copolymers are very interesting tools to 
enhance gene transfer process both in vivo and in vitro and can be used in clinical 
applications. Notably, most interesting aspect of gene transfer in skeletal muscle is the 
associated inflammatory responses and the effects on gene expression, which needs 
careful immunological investigation. Inflammation is a complex response and there are 
drawbacks and benefits to it. However, many inflammatory responses can be modulated, 
wherein Pluronic adjuvants has already found its application and many more adjuvants or 
immune modulators yet need to be explored.  
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CHAPTER 3 
Horizontal Gene Transfer from Macrophages to Ischemic Muscles upon Delivery of 
Naked DNA with Pluronic Block Copolymers  
Abstract 
Intramuscular administration of plasmid DNA (pDNA) with non-ionic Pluronic block 
copolymers increases gene expression in injected muscles and lymphoid organs. We 
studied the role of immune cells in muscle transfection upon inflammation. Local 
inflammation in murine hind limb ischemia model (MHLIM) drastically increased DNA, 
RNA and expressed protein levels in ischemic muscles injected with pDNA/Pluronic. The 
systemic inflammation (MHLIM or peritonitis) also increased expression of pDNA/Pluronic 
in the muscles. When pDNA/Pluronic was injected in ischemic muscles the reporter gene, 
Green Fluorescent Protein (GFP) co-localized with desmin+ muscle fibers and CD11b+ 
macrophages (MØs), suggesting transfection of MØs along with the muscle cells. P85 
enhanced (~4 orders) transfection of MØs with pDNA in vitro. Moreover, adoptively 
transferred MØs were shown to pass the transgene to inflamed muscle cells in MHLIM. 
Using a co-culture of myotubes (MTs) and transfected MØs expressing a reporter gene 
under constitutive (cmv-luciferase) or muscle specific (desmin-luciferase) promoter we 
demonstrated that P85 enhances horizontal gene transfer from MØ to MTs. Therefore, 
MØs can play an important role in muscle transfection with pDNA/Pluronic during 
inflammation, with both inflammation and Pluronic contributing to the increased gene 
expression. pDNA/Pluronic has potential for therapeutic gene delivery in muscle 
pathologies that involve inflammation. 
3.1.       Introduction 
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Direct intramuscular (i.m.) injection of naked plasmid DNA (pDNA) for skeletal 
muscle transfection was pioneered by J.A. Wolff in 1990 (1). As of today i.m. injection of 
pDNA makes up around 18% of worldwide gene therapy human clinical trials (2). These 
trials are related to DNA vaccines, Duchene muscular dystrophy, hind limb ischemia and 
cardiac ischemia (3-5). The i.m. injection of pDNA has shown excellent safety profiles, but 
low gene expression levels, which limits its use in various therapeutic applications. To 
overcome this limitation, we and others have proposed a very simple and inexpensive 
approach of co-administering naked pDNA with non-ionic Pluronic block copolymers 
(“Pluronics” or “poloxamers”) that were shown to drastically increase the levels and 
duration of muscle gene expression (6, 7). Pluronics consist of non-ionic ethylene oxide 
(EO) and propylene oxide (PO) blocks arranged in a basic triblock A-B-A structure: EOx-
POy-EOx. They do not form complexes with the pDNA (8). So far the mechanisms by which 
Pluronic increases the transfection with naked pDNA in skeletal muscles remained not 
well understood. 
It has been known that skeletal muscles have a remarkable ability to 
regenerate after tissue injury, which coincides with the inflammatory events and presence 
of immune cells, in particular, macrophages (MØs). These cells play a key role in the 
process of skeletal muscle regeneration (9-13). Due to constant persistence throughout 
the inflammatory response, MØs help muscle membrane repair in a cell-to-cell contact 
dependent manner (14). Similarly, we know that direct i.m. injection of pDNA also triggers 
an inflammation response due to first, the physical injury caused by the needle, and 
second, the exposure to unmethylated CpG islands in bacterially derived pDNA. A 
previous study reported an increase in muscle transfection of pDNA during hind limb 
ischemia (15). It was already noted before that Pluronic effects pDNA expression in the 
muscle were lacking in immune-deficient athymic mice, which implied the role of immune 
45 
 
45 
 
cells in muscle transfection (8). Moreover, co-administration of Pluronic with pDNA in the 
muscle greatly increased expression of the transgene along with the cDNA and mRNA 
levels in distal lymphoid organs, such as draining lymph nodes and spleen, with the 
transgene being co-localized there with antigen presenting cells (APCs) (16). 
Most disease pathologies involve recruitment of inflammatory cells to the 
tissues and secretion of pro-inflammatory factors either locally or systemically. Since the 
therapeutic genes in the pDNA constructs are driven by constitutive cytomegalovirus 
(cmv) promoter with multiple NF-kb binding sites (17), inflammation may influence the 
gene expression. However, many studies involving i.m. injections of pDNA have been 
conducted in healthy muscles even when the ultimate goal was to use this method for 
therapeutic protein expression in disease-affected tissues. Therefore, studies of the gene 
expression using relatively new platforms such as Pluronic block copolymers in various 
disease models will further help understanding the limits and opportunities for application 
of these platforms in gene therapy. 
The aim of this study was to evaluate the effect of local and systemic 
inflammation on muscle gene expression after i.m. delivery of naked pDNA with or without 
Pluronics. To induce local inflammation, we used a murine hind limb ischemia model 
(MHLIM) and for systemic inflammation both MHLIM and peritonitis. In previous work, we 
ranked the potency of various Pluronics on the expression of a plasmid containing a 
luciferase reporter gene under the control of cmv promoter, and found that Pluronic P85 
(P85) and SP1017 were the most effective and safe (16). Here we examine the effects of 
these copolymers on the MØ ability to take up and express pDNA and horizontally transfer 
the transgene to the muscle cells both during in vitro coculture and adoptive transfer to 
healthy and disease affected animals. 
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3.2. Materials and Methods 
3.2.1. Plasmids.  
The gWIZ™ high expression vectors encoding the reporter genes, luciferase 
(gWIZ™Luc) and green fluorescent protein (GFP; gWIZ™GFP), both under control of an 
optimized human cmv promoter followed by intron A from the cmv immediate-early gene 
were used throughout the study (Gene Therapy Systems, San Diego, CA). The 
pDRIVE5Lucia-mDesmin and pDRIVE5GFP-mDesmin (InvivoGen, San Diego, CA) 
encodes luciferase and GFP reporter proteins respectively, transcribed under the control 
of murine desmin promoter for muscle-specific expression. All plasmids were expanded 
in E. coli DH5α and isolated using Qiagen’s EndoFree Plasmid Giga Kit (Qiagen, Valencia, 
CA) according to the supplier’s protocol, reconstituted in phosphate buffered saline (PBS) 
and stored at -20oC until use. 
3.2.2. Block copolymers.  
Pluronic L61 (batch # WPNT-511B), P85 (batch # WPNT-511B), F127 (batch 
# WPNT-511B), were a gift of the BASF Co. (Mount Olive, NJ). A mixed composition of 
L61 (0.25% w/v) and F127 (2% w/v), SP1017 (2.25% w/v) was obtained from Supratek 
Pharma Inc. (Montreal, Canada) or prepared using the corresponding copolymers. 
3.2.3. pDNA/Pluronic formulations.  
The pDNA formulations were prepared as described (16) and used 
immediately for i.m. injections. 
3.2.4. Cells.  
RAW264.7 immortalized mouse MØs cell line and C2C12 immortalized 
myoblasts (MBs) cell line were purchased from ATCC and cultured at 370C and 5% CO2. 
To obtain terminally differentiated skeletal myotubes (MTs), C2C12 MBs were plated in 
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96-well plates (50,000 cells/well) in complete media (CM) containing Dulbecco’s minimal 
essential media (DMEM) and 10% fetal bovine serum (FBS). After 24 h or ~100% 
confluence, CM was replaced with 200 μl/well differentiation media (DM) containing 
DMEM and 2% horse serum (HS) to facilitate fusion of MBs (18). DM was changed every 
12 h thereafter until day 5-10 when healthy long differentiated MTs were formed. 
3.2.5. Animals.  
All animal experiments were carried out with approval of the University of 
Nebraska Medical Center (UNMC) and University of North Carolina at Chapel Hill (UNC-
CH) Institutional Animal Care and Use Committee and in accordance with the NIH Guide 
for Laboratory Animal Use. Female Balb/c mice (6- to 8-weeks-old, Charles River 
Laboratories, Wilmington, MA) were used throughout this study. The animals were kept in 
groups of five and fed ad libitum.  
3.2.6. Inflammation models and scheme of experiments.  
MHLIM was generated by surgical procedure as described (19, 20). Briefly, 
under general anesthesia, the femoral artery (FA) of right hind limb was completely 
excised after ligation at its proximal origin as a branch of the external iliac artery and before 
the point distally where it bifurcates into the saphenous and popliteal arteries. Saphenous 
artery and saphenous vein were also excised. An interval of 10 days was allowed for 
postoperative recovery before DNA administration in ischemic tibialis anterior (TA) muscle 
by direct i.m. injections. In some groups MHLIM surgery was performed on ipsilateral hind 
limb and test articles were simultaneously injected in contralateral TA muscles of the same 
mouse. Peritonitis was induced by intraperitoneal (i.p.) injections of filter-sterilized λ-
carrageenan (CGN; 1 mg/200 µl PBS) on the 1st and 2nd day and followed by test articles 
injections in TA muscles on the 3rd day. In some groups pDNA and Pluronic were in 
administered in separate legs in both healthy and peritonitis model. 
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3.2.7. pDNA injections.  
Animals were anesthetized by i.p. injection of mixed solution of ketamine (100 
mg/kg) and xylazine (25 mg/kg) (Sigma, St. Louis, MO). Single injection of pDNA in 50 µl 
of Hank’s balanced salt solution (HBSS) alone or 50 µl of the block copolymer solution in 
HBSS was administered directly into right TA muscle of the mice using 28G 1 cc sterile 
syringe (BD Bioscience, Franklin Lakes, NJ).  
3.2.8. Luciferase activity in vivo.  
Unless indicated otherwise mice were euthanized at the time points indicated 
in the figure legends and tissues were processed. The luciferase activity in 10 µl tissue 
homogenates was quantified using a TD20/20 or Glomax 20/20 luminometer (Promega, 
Fitchburg, WI) for an integration period of 20 s and 10 s respectively and normalized per 
mg of tissue as described before (16). Alternatively, luciferase activity was measured in 
live animals using in vivo imaging system IVIS-200 (Xenogen Corporation, Alameda, CA) 
5 min after i.p injection of D-Luciferin and the imaging data were quantified as described 
before (16). 
3.2.9. Polymerase Chain Reaction (PCR).  
PCR and Reverse transcription PCR (RT-PCR) were performed as described 
in (16). 
3.2.10. Percent White Blood Cell (WBC) count in blood samples.  
Fresh serial blood samples from the tail vein (30-40 μl), collected into EDTA 
coated capillaries by tail milking method, were analyzed in VetScanHM5 hematology 
analyzer (Abaxis Ltd, Union City, CA) and % WBC counts were plotted on a time scale 
(days) after ischemia surgery 
3.2.11. Tissue Histology.  
49 
 
49 
 
Muscle tissues [quadriceps (Q), adductor (A), gastrocnemius (G) and TA)] at 
specified time points were removed en bloc and processed as described earlier (16). 
3.2.12. Adoptive transfer of GFP transfected MØs in ischemic mice.  
RAW 264.7 MØs were plated in vitro in T75 flask in macrophage colony 
stimulating factor (MCSF) supplemented CM for 24 h and transfected with gWIZTM GFP 
pDNA using genePORTER300 transfection reagent as per supplier’s protocol 
(extrapolated from 60 mm2 dish to T75 flask based on surface area). After another 24 h, 
5X106 MØs were injected to ischemic mice by intrajugular vein injection (i.j.v.) 48 h post 
ischemic surgery. Ipsilateral ischemic and contralateral healthy muscle tissues were 
isolated 3 days after adoptive transfer of MØs (5 days post-surgery), embedded and 
frozen. (Time point of tissue isolation was determined in a separate study where 
biodistribution of fluorescently labelled and MCSF polarized or M2-MØ, and unpolarized 
MØ was determined by IVIS imaging Fig. S3.15). 10 µm tissue sections were processed 
for immunohistochemistry (IHC) as described in (16). 
3.2.13. Cytotoxicity evaluation.  
Cytotoxicity was determined using the CellTiter® 96 Aqueous Cell Proliferation 
Assay (MTS assay) (Promega, Fitchburg, WI) as per manufacturer recommendations. 
Briefly, cells (20,000 MØs, 16,000 MBs or day 7 MTs per well) were seeded in a 96-well 
plate 24 h before the experiment. Cells treated with Pluronic solutions in 100 μl of serum 
free media (SFM) for 2, 4, 6 and 8 h were rinsed thrice with SFM and cultured in CM.  After 
another 24 h, cells were incubated with a mixture of 100 μl SFM + 20 μl MTS assay reagent 
for 1 h at 37°C at 5% CO2 and finally, calorimetric readout at 490 nm was done using 
Spectramax M5 plate reader (Molecular Devices, Sunnyvale, CA). The results were 
expressed as the mean percentage cell viability relative to untreated cells ± SEM (n=6). 
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3.2.14. In vitro luciferase gene expression.  
To study the effects of P85 on gene expression, 500,000 MØs were plated in 
24-well plates in antibiotic free media. 24 h later, cells were treated with mixture of 
gWIZ™Luc in different concentrations of P85 in SFM for 2h, and cultured in CM. After 
another 24 h, luciferase activity was measured in cell lysates as described in (16). 
Luciferase activity in coculture experiments (below) was measured in 10 μl cell lysates 
(cmv-coculture model) or 10 μl supernatant media (desmin-coculture model) using 
luciferase assay reagent or Quantiluc® respectively. The data was integrated over 10 s. 
Total protein content was measured using PierceTM BCA Protein Assay Kit (Thermo-
Fisher Scientific Inc, Waltham, MA) and data was expressed as RLU/mg protein. 
3.2.15. Gene expression in coculture.  
RAW 264.7 MØs were transfected with either gWIZ™Luc or pDRIVE5Lucia-
mDesmin plasmids using genePORTER® 3000 transfection reagent (Genlantis, San 
Diego, CA) as per supplier’s recommended protocol. To remove membrane bound 
complexes after transfection prior to coculture, transfected MØs were briefly rinsed with 
1mg/ml heparin sulphate solution in PBS, followed by two times rinse with PBS and  this 
procedure was repeated twice. MØs were then resuspended in CM and 50,000 MØs were 
added on top of 50,000 MBs or MTs in each well. Exactly after 2 h when MØs adhere to 
MBs or MTs, the coculture was rinsed with SFM (thrice) to remove traces of serum and 
exposed to SFM with/without P85 (0.01%, 0.1%, 0.3% and 1.0% w/v) for another 2 h, 
rinsed again with SFM (thrice) and cultured in 280 μl CM. After 24 h, gene expression was 
analyzed as described above. To study time-course of gene expression in coculture, the 
media was replaced every 12 h and samples were collected at the defined time points. 
For confocal imaging, gWIZ™GFP or pDRIVE5GFP-mDesmin plasmid were used. At 
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different time points, post coculture samples were fixed and labeled as explained in 
immunocytochemistry (ICC) in Supplementary Methods.   
3.2.16. Western blotting.  
Cell lysates prepared using mammalian protein extraction reagent (M-PER®; 
Pierce Biotechnology, Rockford, IL) were mixed with 2x Laemmli sample buffer (Bio-Rad 
Laboratories, Hercules, CA), boiled for 5 min and separated on a precast 12% SDS-PAGE 
gel (Bio-Rad Laboratories, Hercules, CA). Proteins were transferred on PVDF 
membranes, blocked with 5% w/v skim milk and probed overnight (o/n) with antibodies 
against β-actin (Abcam, Cambridge, MA) and desmin (Abcam, Cambridge, MA) at 4oC 
with gentle shaking. Membranes were washed with tris-buffered-saline (TBS) containing 
0.1% w/v tween and probed with goat anti-rabbit IgG-HRP (Santa Cruz Biotechnology, 
Dallas, TX) and donkey anti-goat IgG-HRP (Abcam, Cambridge, MA) for 1 h at room 
temperature (RT) with gentle shaking before visualizing the protein bands using PierceTM 
ECL Western Blotting substrate (Thermo Fisher Scientific, Waltham, MA).  
3.2.17. Statistical analysis.  
Student’s t-test was used to calculate statistical significance with p <0.05 
(unless indicated) in all cell culture and animal experiments except Fig. 3.1a, b where p 
values were obtained using Student’s t-test following logarithmic transformation of the 
data.
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3.3. Results 
3.3.1. Pluronic enhances gene expression during local inflammation in MHLIM 
It was reported that co-injection of Pluronics with pDNA into the TA muscle of 
healthy animals increases and prolongs the gene expression compared to the naked 
pDNA (16). Here, to determine the effect of copolymers on the gene expression in the 
inflamed muscle of the disease-affected animal, we established and characterized MHLIM 
using previously described procedures (19, 20). The ischemia and tissue inflammation in 
this model were validated by histological examination of various ischemic muscle sections 
(as presented in supplementary information Fig. S3.1). This model shows a typical 
response consistent with inflammatory cellular infiltrate. The pDNA, with or without 
Pluronic (P85 or SP1017), was injected into ischemic TA muscle of MHLIM on day 10 after 
surgery (“ischemic muscle” injections). In parallel experiments, same pDNA formulations 
were injected in the healthy mice (“healthy muscle” injections). The expression of 
luciferase was determined in the muscle homogenates on day 4 after injection, as 
previously described (8). The results suggested that P85 and SP1017 increased the 
luciferase expression in a dose-dependent manner, revealing typical bell-shaped 
dependencies of the expression vs. copolymer concentration, (Figs. 3.1a, b) in both 
ischemic and healthy muscles. However, there was a shift in the optimal concentration of 
Pluronic in the ischemic muscles, where the maximal expression was observed at higher 
concentration of the copolymers compared to the expression in the healthy muscles (0.6% 
vs. 0.3% w/v for P85 and 0.1% vs. 0.01% w/v for SP1017). At the maximum, in ischemic 
muscles, the expression levels of pDNA/copolymer mixtures were increased compared to 
the naked pDNA by ca. 72 fold for pDNA/P85 and 26-fold for pDNA/SP1017. Moreover, 
the maximal gene expression in ischemic muscles exceeded that in healthy muscles by 
ca. 8- and 3-fold for pDNA/P85 and pDNA/SP1017 respectively. Interestingly, the 
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expression of naked pDNA also somewhat increased in ischemic muscles compared to 
that in healthy muscles. 
We further determined the pDNA dose response on the gene expression by 
injecting different doses (5 μg, 10 μg and 50 μg) of naked pDNA or pDNA/Pluronic 
(SP1017, 0.1% w/v) into ischemic muscle. The results suggested that the optimal dose of 
pDNA/SP1017 was 10 μg in 50 µl HBSS (Fig. 3.1c), and this dose was same as the one 
previously reported for healthy animals (8). At the lower dose of 5 μg, the levels of gene 
expression declined. At the higher dose of 50 μg, the gene expression leveled off and was 
not significantly different from that observed at 10 μg pDNA. Therefore, 10 μg pDNA was 
selected for further injections. 
Next, the naked pDNA or pDNA/Pluronic was injected into ischemic and 
healthy muscles and the levels of luciferase pDNA and mRNA were determined 4 days 
after injection as previously described (16). The results suggested that Pluronic (SP1017, 
0.1% w/v) increased pDNA and mRNA levels in healthy as well as in ischemic muscles 
compared to the animals injected with pDNA alone (Fig. 3.1d). Interestingly, the levels of 
DNA and mRNA in MHLIM injected with pDNA alone were considerably higher compared 
to these levels in the healthy animals (Fig. 3.1d). 
Our previous studies showed that Pluronic prolongs transgene expression in 
the muscle of healthy Balb/c mice up to several weeks (21). Here we determined the time 
course of the luciferase expression in the ischemic TA muscle of MHLIM by quantifying 
luciferase bioluminescence in live animals (Fig. 3.1e and Supplementary information Fig. 
S3.2). The areas under the curve (AUC) for the 60 days period were determined for all 
groups using the trapezoidal rule. When comparing the ischemic and healthy muscles 
injected with the naked pDNA, the former displayed much higher gene expression at every 
time point. Moreover, the gene expression was further significantly enhanced and 
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prolonged when pDNA was formulated with SP1017, resulting in increased exposure of 
the animal to the transgene by nearly an order of magnitude for at least 50 days. Thus, 
the AUC values in the MHLIM injected with pDNA/SP1017 and naked pDNA were 2186 
and 312 day*photons/s*106, respectively, suggesting ca. 7-fold increase in the transgene 
expression as a result of the pDNA formulation with SP1017. For comparison, in healthy 
animals the corresponding AUC values for pDNA/SP1017 and naked pDNA were 597 and 
150 day*photons/s*106 respectively.  
The GFP reporter gene expression in ischemic TA muscles, harvested on day 
4 after gWIZTM GFP pDNA injection, was mainly seen in the muscle fibers located in and 
around the site of the injection, and co-localized with desmin muscle marker (Fig. S3.3a). 
Also, a substantial GFP expression was observed in small punctate cells, uniformly spread 
throughout ischemic tissue section, and co-localized with CD11b MØ marker (Fig. S3.3b). 
Interestingly, the number of GFP expressing CD11b+ MØs in ischemic muscles appeared 
to be much higher than previously reported by us in non-inflamed muscles of the same 
mouse strain (16). Moreover, we also observed a higher number of GFP expressing 
muscle fibers in ischemic muscles injected with pDNA/P85 compared to pDNA alone (Fig. 
S3.4 and Fig. S3.5).
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Figure 3.1. Effect of co-formulation of pDNA with Pluronic on the transgene expression, DNA 
and RNA levels in healthy and ischemic skeletal muscles. Luciferase expression (a-c, e) or 
DNA and RNA levels (d) in ischemic TA muscles of MHLIM (a-e) or normal TA muscles of healthy 
animals (a, b, d, e) after single injections of the pDNA, pDNA/P85, or pDNA/SP1017. (a-e) All 
injected solutions contained 10 µg gWIZ-Luc pDNA in 50 µl HBSS with or without copolymers 
except (c) where the pDNA concentration was varied. (c-e) SP1017 concentration in injected 
solution was 0.1 % w/v. (a-d) Measurements were done on day 4 by tissue sampling. (e) Time 
course of luciferase expression was determined in live animals by quantifying the bioluminescence 
imaging data (supplementary Fig. S2). (a-c, e) Data are mean + SEM (a-c) n = 5, * p < 0.05, n.s. 
– not significant or (e) n = 3-4. 
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3.3.2. Pluronic enhances gene expression in muscle during systemic 
inflammation 
MHLIM was accompanied by systemic inflammation as evidenced by increase 
in neutrophils and MOs count in blood (Fig. 3.2a). Therefore, we examined the effect of 
inflammation during MHLIM on the transgene expression in the distal muscle. In this 
experiment the MHLIM was developed as described before, but the site of pDNA injection 
was spatially separated from the inflammation site (Fig. 3.2b). Naked pDNA alone or 
pDNA/Pluronic were injected in contralateral TA muscle simultaneously with the ischemia 
surgery performed on ipsilateral hind limb, and gene expression levels in muscles and 
draining lymph nodes were quantified in tissue homogenates at day 3. Consistent with our 
previous studies (8, 16) in healthy mice P85 significantly increased gene expression 
compared to pDNA alone. The ischemia surgery in MHLIM resulted in a further dramatic 
increase in the expression, both in contralateral muscle (Fig. 3.2c) and lymph nodes (Fig. 
3.2d). Importantly, the effect of inflammation on gene expression was only observed with 
pDNA/P85 and not with pDNA alone. The effects appeared to be dependent on the type 
of the copolymer used since they were not significant for the pDNA/SP1017 
(Supplementary information Fig. S3.6). 
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Figure 3.2. Effect of skeletal muscle ischemia on transgene expression in contralateral 
muscles. (a) Changes in percent WBC counts in serial blood samples at different time points after 
ischemia surgery in MHLIM (solid lines, flied symbols) in comparison to healthy mice (dotted lines, 
open symbols). Day 0 corresponds to surgery. (b) Test articles were injected in TA muscles in 
healthy mice or in contralateral TA muscles simultaneously with the ipsilateral ischemia surgery in 
MHLIM.  (c, d) Luciferase gene expression in the (c) TA muscles and (d) draining lymph nodes of 
MHLIM (black) and healthy mice (white) 3 days after single administration of 10 µg gWIZ™ Luc 
with or without 0.3 % w/v P85. Data are mean ± SEM (n = 3 (a) or n = 10 (c, d)), * p < 0.05, **p<0.01, 
****p<0.001, n.s. – non significant. (a) Statistical comparisons were made between MHLIM and 
healthy mice. 
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The effect of inflammation on Pluronic-mediated gene expression at a distal 
site was striking and led to another experiment using peritonitis model to confirm the 
generality of the observation. Similar to MHLIM, systemic inflammation in peritonitis 
mouse model was confirmed by quantifying percent WBCs by hematological analysis of 
serial blood samples from tail vein (Fig. 3.3a). In this experiment, in addition to pDNA 
alone and pDNA/P85 groups, we included an additional group injected with P85 and pDNA 
in spatially different hind limb muscles (Fig. 3.3b). Since effect of P85 was more 
pronounced, we did not use SP1017 in this experiment. Luciferase reporter gene 
expression was quantified by in vivo imaging after i.p. injection of D-luciferin substrate. 
Similar to our observations in ischemia model, animals with peritonitis showed a trend to 
increase gene expression in muscle compared to healthy animals (Fig.  3.3c). Mice 
injected with naked pDNA in ipsilateral leg and P85 in contralateral leg (DNA, P85) showed 
gene expression levels similar to naked pDNA alone suggesting that increased muscle 
transfection is dependent on codelivery of P85 with pDNA. Still, the contralaterally injected 
P85 significantly increased gene expression of pDNA in ipsilateral muscle in the peritonitis 
animals (Figs. 3.3c, d).
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Figure 3.3. Effect of peritonitis on transgene expression in skeletal muscles. (a) Changes in 
percent WBC counts in serial blood samples at different time points after induction of peritonitis 
(solid lines, filled symbols) in comparison to healthy mice (dotted lines, open symbols, same group 
as in Fig. 2). Day 0 corresponds to the first injection of CGN to induce peritonitis.  (b) Healthy mice 
or mice with peritonitis were injected in TA muscles with 10 µg gWIZ™ Luc pDNA alone, pDNA 
coformulated with 0.3 % w/v P85 or simultaneously injected in ipsilateral and contralateral TA 
muscles with pDNA and 0.3 % w/v P85. (c) Luciferase gene expression in pDNA injected muscle 
of healthy (white bars) and peritonitis (black bars) mice was quantified using by quantifying the 
bioluminescence imaging data 4 days after pDNA administration. (d) Representative IVIS images 
used for quantification of gene expression data 4 days after pDNA administration. (a, c) Data are 
mean ± SEM (n=3), * p < 0.05, n.s. - non significant. (a) Statistical comparisons were made for 
peritonitis v.s. healthy mice groups.  
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3.3.3. Pluronic enhances transfection of MØs with pDNA in vitro 
Since in vivo study suggested colocalization of the reporter gene with MØs 
(Fig. S3.3), we examined whether Pluronics can enhance transfection of MØs with pDNA 
in vitro. To this end we exposed RAW 264.7 cells for 2 h to pDNA at various concentrations 
of P85 and quantified luciferase in cell lysates 24 h after the exposure. Addition of P85 to 
the media, at the concentration as low as 0.01%, resulted in a significant enhancement of 
the gene expression (Fig. 3.4a). This effect increased as the copolymer dose increased 
and reached over 4 orders of magnitude at 1% P85 concentration when the gene 
expression levels nearly matched that observed using a commercial transfection kit, 
genePORTER® 3000. Moreover, at the higher dose of pDNA (10 µg) the gene expression 
with 1.0% w/v P85 exceeded that using genePORTER® 3000 transfection (Fig. 3.4b). 
Analysis of pDNA uptake in the cells showed higher pDNA uptake in MØs than muscle 
cells and significant although marginal increase of pDNA uptake in MØs in the presence 
of P85 (Supplementary information Fig. S3.7). No such increase in uptake was observed 
in cultured muscle cells with the addition of P85 (MBs or MTs). Other Pluronic block 
copolymers also showed a similar effects on gene expression in RAW 264.7 cells (Fig. 
S3.14)
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Figure 3.4. Effect of Pluronic on the gene expression in RAW 264.7 MØs. (a, b) Cells were 
exposed to gWIZ™ Luc pDNA with or without P85 in SFM (a) for 2 h using 1 µg pDNA and various 
concentrations of P85 or (b) for 4 h using different amounts of pDNA (1 µg, 5 µg and 10 µg) and 
1.0% w/v P85. (a, b) Cells transfected using genePORTER® 3000 transfection reagent are 
presented as positive control. Data are mean ± SEM (n=4), * p<0.05, n.s. – non significant, 
statistical comparisons were done for treated vs. untreated groups unless specified different. 
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3.3.4. Adoptive gene transfer to muscle by ex vivo transfected MØs 
To examine whether MØs can transfer genes to ischemic animals, the RAW 
264.7 MØs were transfected ex vivo with gWIZTM GFP using genePORTER 3000 and 
adoptively transferred via jugular vein to MHLIM animals 24 h post transfection and 48 h 
post ischemia surgery. The lower hind limb muscles (ischemic and non-ischemic) were 
isolated 3 days after MØs administration, sectioned and analyzed by confocal imaging for 
co-localization of GFP with CD11b+ MØs and desmin+ muscle fibers. Firstly, we found that 
GFP expressing MØs were recruited to ischemic muscles and not to non-ischemic 
muscles of MHLIM (Fig. 3.5). Secondly, the GFP expression in ischemic tissues co-
localized with desmin+ muscle fibers as seen in Fig. 3.5. Larger ischemic muscle fibers 
clearly expressed GFP protein unlike non-ischemic control muscles. This implied that MØs 
can transfer GFP gene across the muscle cell membrane, and along with the muscle cells 
can collectively represent a reservoir or conduit for the gene expression. We observed 
lower levels of muscle-specific marker (desmin) in ischemic muscle compared to non-
ischemic muscle, which is typical for ischemia (24, 25). Importantly, in ischemic muscles 
CD11b+ MØs were localized in close proximity to muscle fibers as was seen from co-
localization of desmin and CD11b. This may imply that cell-to-cell contacts play role in 
exchange of genes or proteins from MØs across the cell membranes to otherwise hard to 
transfect skeletal muscle fibers. 
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Figure 3.5. In vivo transfection of muscle cells upon adoptive transfer of GFP transfected 
MØs. RAW 264.7 MØs transfected ex vivo with gWIZTM GFP pDNA and administered i.j.v in MHLIM 
Balb/c mice (24 h after transfection, 48 h post ischemia surgery). Tissues (TA and G) were isolated 
3 days thereafter and 10 µm thick sections of frozen tissues were processed for IHC. The color 
staining corresponds to nuclear DAPI (blue), GFP (green), CD11b (red) and desmin (magenta). 
The bottom panels present digitally superimposed images of preceding panels to visualize the co-
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localization (yellow or white). The images (20 x) are representative of 3 sections per muscle and 3 
mice per group. Scale bar = 50 µm. 
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3.3.5. In vitro horizontal gene transfer from transfected MØs to muscle cells  
To further examine pDNA transfer from MØs to muscle cells at the cellular 
level, we developed an in vitro coculture model. Briefly, gWIZTM GFP transfected MØs 
were co-cultured with MBs, and GFP expression in MØs and MBs was visualized by 
confocal imaging at different time points. As shown in Fig. 3.6, we clearly observed GFP 
expression in desmin+ MBs after 48 h and 72 h coculture with transfected MØs. Notably, 
MBs stained positive for MØ marker (CD11b) and not vice versa implying a unidirectional 
transfer of membrane components from MØs to MBs upon coculture, which may explain 
the mechanism of delivering pDNA/protein across the membranes resulting in muscle cell 
transfection. Our observation was similar to other reports that describe bi/uni-directional 
exchange of membrane components as a general cell-to-cell communication amongst 
various cell types (26-28). 
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Figure 3.6. In vitro transfection of muscle cells upon coculture with GFP transfected MØs. 
MØs (arrow heads) were transfected with gWIZ™ GFP pDNA and then cocultured with un-
transfected MBs (arrows) for up to 72 h. At specific time points cells were harvested and processed 
for ICC. MBs stained positive for both GFP and CD11b at each time point. The color staining 
corresponds to GFP (green), CD11b (red), and desmin (cyan). The bottom panels present digitally 
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superimposed images (20 x) of preceding panels to visualize the co-localization (yellow or white). 
Scale bar = 50 µm. 
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3.3.6. Pluronic enhances horizontal transfer of pDNA from MØs to muscle cells  
After demonstrating that Pluronic can enhance the transfection of MØs with 
pDNA, we further examined whether it could also increase the pDNA transfer from the 
transfected MØs to muscle cells. To evaluate such possibility, we studied in vitro effect of 
P85 on the transgene expression in the coculture of transfected MØs with muscle cells. 
First we transfected the constantly multiplying RAW 264.7 MØs with pDNA [MØ+DNA] 
and then cocultured them on top of the monolayers of 1) either terminally differentiated 
C2C12 MTs (depicted herein [MØ+DNA]+MT), or 2) precursor MBs ([MØ+DNA]+MB). 
Notably, MTs display high level of expression of desmin, which is much lower in MBs (Fig. 
3.7a). Thus we used two different plasmids, one with the constitutive (cmv) promoter, 
gWIZ™ Luc pDNA (same as the plasmid used above), and the other with the muscle 
specific-desmin promoter, pDRIVE5Lucia-mDesmin (to quantify the muscle specific gene 
expression). In both cases, the transfected MØs or the cocultures were exposed to 
different concentrations of P85 (0.01, 0.1, 0.3, 1.0% w/v) for 2 h and the total gene 
expression was determined after 24 h and normalized to the total protein. Using the 
desmin-driven pDNA we observed relatively low levels of normalized gene expression in 
all cell systems - [MØ+DNA], [MØ+DNA]+MT, and [MØ+DNA]+MB (Fig. 3.7b). In the 
transfected MØs the gene expression was increased at 0.01% P85, while at higher 
copolymer concentrations it was either less or not significantly different compared to 
untreated controls. In [MØ+DNA]+MB coculture the gene expression was not statistically 
different from the control in all but the highest P85 concentration group, in which it was 
significantly decreased. In contrast, [MØ+DNA]+MT coculture after exposure to the 
copolymer displayed a trend for a monotonous increase in the normalized gene 
expression, this increase becoming significant at 1% P85. At this copolymer concentration 
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the total gene expression in [MØ+DNA]+MT coculture was much higher than that in 
[MØ+DNA] and [MØ+DNA]+MB (Supplementary information Fig. S3.8).  
Therefore, we further examined the gene expression in [MØ+DNA] and 
[MØ+DNA]+MT coculture at different time points after exposure to 1% P85 (Fig. 3.7c). In 
this case starting from day 2 there was a dramatic increase in gene expression in 
[MØ+DNA]+MT coculture but not in the transfected MØ alone. Compared to the coculture 
the level of gene expression in MØ+DNA was negligible with or without exposure to P85. 
The latter is probably explained by the promoter selectivity of the pDRIVE5Lucia-mDesmin 
plasmid used in this study as well by some toxicity of the 1% P85 to macrophages 
(Supplementary information Fig. S3.9). Notably, when similar co-culture experiments 
were carried out using constitutive (cmv) promoter driven gWIZ™ Luc pDNA, both the total 
and normalized gene expression in MØ+DNA groups after 24 h was high (Supplementary 
information Fig. S3.10 and S3.11). However, at later time points the normalized gene 
expression in MØ+DNA sharply decreased while in the coculture it increased, especially 
in the groups treated by P85 (Supplementary information Fig. S3.10). Using plasmids 
expressing GFP in the [MØ+DNA]+MT coculture groups, we were able to clearly see gene 
expression in the MTs (Fig. 3.7d and Supplementary information Fig. S3.11c). This result 
is particularly amazing given the fact that MTs are most difficult to transfect cells using 
normal cell transfection means (Supplementary information Fig. S3.12).
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Figure 3.7. Effect of P85 on horizontal gene transfer from transfected MØs to muscle cells 
upon co-culture. (a) Increased desmin expression upon differentiation of MBs to day 7 MTs. (b, 
c) pDRIVE5Lucia-mDesmin transfected MØs were plated alone, [MØ+DNA], or cocultured with 
MBs, [MØ+DNA]+MB,  or MTs, [MØ+DNA]+MT, and exposed to P85 (0.01, 0.1, 0.3 and 1.0 % (b) 
or 1 % w/v (c)) for 2 h. Luciferase secreted in cell culture media was quantified after next 24 h (b) 
or at different time points. In the latter case (c) the media was replaced every 12 h and luciferase 
secreted in the media over 6 h period was determined daily until day 10. Data represents mean ± 
SE, * p<0.05, n.s. – non significant (b) (n=6), (c) (n=12), statistical comparisons were done for 
coculture with and without P85 treatment vs. MØ+DNA groups alone and the curves were 
compared using AUC and one-way ANOVA analysis. (d) GFP expression (green) in desmin+ MTs 
(cyan) was validated 3 days after their coculture with CD11b+ MØs (red) transfected with gWIZ™ 
GFP pDNA. The last panels in each row present digitally superimposed images (20 x) of preceding 
panels to visualize the co-localization (yellow). Scale bar = 50 µm. 
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3.4. Discussion 
Administration of pDNA to skeletal muscle is a strategy to deliver various genes 
for prophylactic and therapeutic purposes in healthy and diseased muscles (29-31). 
Currently, the application of direct i.m. pDNA injections is hindered by low levels of gene 
expression. Improvements in this area include electroporation-facilitated gene transfer 
known for its simplicity and use in human clinical trials (32). However, electroporation is 
associated with the risk of extensive and irreversible muscle damage induced by electrical 
pulses (33). This has limited its application in therapeutics, especially, when the goal is to 
rescue the muscle fibers during muscular pathologies, such as hind limb ischemia, 
polymyositis, muscular dystrophies, etc. Most of these pathologies involve inflammation 
and recruitment of inflammatory cells, which further contribute to tissue degeneration and 
muscle damage (34, 35). We have reported that coadministration of pDNA with non-ionic 
amphiphilic Pluronic block copolymers leads to drastic increases in the level and duration 
of transgene expression in the healthy muscles (6, 8). In contrast to electroporation, 
muscle tissue did not appear to be affected by pDNA/Pluronic mixture as observed by 
histological analysis (16) and animals injected with these formulations did not show any 
signs of discomfort. Furthermore, Pluronic was coadministered with pDNA in the muscle 
during electroporation, where it alleviated the pulse-induced tissue damage and further 
increased the transgene expression (36). 
Here, we report supplementary effects of Pluronic and inflammation caused by 
muscle ischemia on the transgene expression in the muscle. The greatest expression was 
observed in MHLIM when pDNA/Pluronic was injected directly in the ischemic muscle, 
although a significant increase compared to expression in healthy animals was also seen 
when the site of injection was distal from the ischemia site. The latter suggests that 
systemic inflammation contributes to the pDNA/Pluronic gene delivery in the muscle. This 
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conclusion was also reinforced by an observed increase in muscle transgene expression 
with pDNA/Pluronic during systemic inflammation in the peritonitis model. Interestingly, 
the effects of Pluronic were much higher when Pluronic was co-delivered with pDNA in 
the same muscle than upon their separate administration in different muscles. Still in the 
latter case gene expression in peritonitis model was increased possibly suggesting 
systemic distribution and effect of Pluronic. In the absence of Pluronic inflammation had 
little if any effect on pDNA expression during peritonitis and relatively small effect in 
MHLIM. Notably, other studies also reported that inflammation could enhance muscle 
gene expression upon direct i.m. injection of naked pDNA (15, 37). 
Previously published data suggested that Pluronics do not enhance muscle 
transfection in immune-deficient athymic nude mice (8, 38), which implied a mutually 
inclusive role of both immune cells and copolymers in the muscle transfection. We have 
also reported that 1) transgenes can be transferred from in vitro transfected MØs to the 
surrounding cells (e.g. neurons) upon coculture and 2) that after adoptive transfer, 
transfected MØs can deliver transgenes to the distal sites of inflammation, specifically to 
the brain in the mouse model of Parkinsonism (22, 23). These studies suggested that 
transfected MØs can repackage pDNA and deliver across cell membranes to neuron cells 
via exosomes and other extracellular vesicles. The present study reinforces the idea that 
Pluronic may assist muscle transfection through the effects on immune cells and 
specifically MØs that are recruited in the inflamed muscles, pick up the pDNA and express 
the transgene. MØs are known to internalize bacterial derived pDNA by a very specific 
transport mechanism resulting in gene expression both in vitro (39) and in vivo (40). Here 
we demonstrate that treatment with Pluronic increases the transfection of MØs with naked 
pDNA and boosts gene expression up to 4 orders of magnitude. Moreover, after adoptive 
transfer in MHLIM the transfected MØs are shown to deliver transgene to the ischemic but 
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not the healthy muscles. These observations suggested that MØs can transfer transgene 
across the muscle cell membrane, and led to specific experiments using in vitro coculture 
models. 
In these experiments we demonstrated that MØs can horizontally transfer 
pDNA to muscle cells and this process is greatly enhanced in the presence of Pluronic. 
Interestingly, we observed a unidirectional exchange of MØs cell surface marker (CD11b) 
to muscle cells but not vice versa. This phenomenon may be in common with the 
evolutionary process, by which MØs recruited to the site of muscle damage deliver growth 
factors required for muscle regeneration. Recent studies have also reported a novel 
mechanism of vesicular exchange of protein/genetic material between APCs during cell-
to-cell communication (41), which justifies our observations. Using horizontal gene 
transfer with Pluronic we were able to transfect MTs that are terminally differentiated cells 
and therefore notoriously difficult to transfect in vitro. That is why researchers use 
transiently transfected mitotically active MBs and differentiate them to form transfected 
MTs. This procedure limits the skeletal muscle biology studies to early stages of muscle 
development. Our finding provides a novel approach for gene delivery to MTs at later 
stages (1-3 weeks) after differentiation and can find application in research labs. 
Skeletal muscles are known for complex muscle biology, and recent studies 
have shown that MØs play a significant role in helping muscle regeneration and preventing 
muscle atrophy (9, 42-44) via cell-to-cell contacts (14). The role of stem and hematopoietic 
cells in muscle regeneration has been also extensively studied (45, 46). Evidence points 
to involvement of cell-to-cell fusion in muscle regeneration, whereby cells with stem cells’ 
properties fuse with damaged muscle fibers or satellite cells to form new muscle fibers. 
Technologies to deplete and repopulate specific cells including transgenic mice were 
developed and showed that the stem cells with myeloid cell properties are responsible for 
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muscle regeneration (13, 47, 48). Similar mechanisms were reported for regeneration of 
liver by MØs fusion (49-51). Therefore, we posit a mechanism in which MØs are recruited 
to the sites of naked pDNA injections as a result of physiological insult caused by needle 
injury. These MØs phagocytose extracellular naked pDNA and then fuse with the existing 
muscles as a part of regeneration process thus, delivering pDNA into otherwise hard to 
transfect skeletal muscles. Based on our observations Pluronic can enhance both the 
transfection of the MØs with pDNA and the horizontal gene transfer from the transfected 
MØs to muscle fibers. Previously polyethylene glycol (PEG) mediated cell-to-cell fusion 
has been extensively studied to generate somatic cell hybrids for cloning, gene mapping, 
gene expression and antibody production 1970s (12, 52, 53). The proposed model 
involves exclusion of water molecules between lipid bilayers and changing the orientation 
of molecular dipoles that results in membrane fusion (54). Since Pluronics contain PEG 
as well as polypropylene glycol chains capable of incorporating into lipid membranes (55), 
we believe that they can enhance the MØs to muscle cell fusion events eventually 
delivering pDNA to muscle fibers and increasing transfection and gene expression both in 
healthy and inflamed muscles.  
It is known that after direct i.m. injection in skeletal muscle naked pDNA is 
rapidly degraded in extracellular matrix (56, 57). Therefore, is noteworthy that we 
observed a block copolymer-dependent increase in pDNA copies in both healthy and 
ischemic muscles. Unlike cationic lipids or polycations, Pluronics are non-ionic molecules 
and do not form complexes with pDNA that can protect it from the degradation in the 
extracellular matrix similar to lipoplexes/polyplexes (16, 58). However, Pluronics can act 
as adjuvants that activate NF-kB cell signaling and increase pDNA uptake (59), pDNA 
nuclear import (60) and transcriptional activation of gene expression of pDNA delivered 
into cells in vitro with polyplexes (61, 62). It is well-known that inflammation results in 
76 
 
76 
 
increased blood neutrophils counts and secretion of pro-inflammatory cytokines like TNF 
alpha and IL-1β (63). The overall activation of inflammatory signaling can also influence 
cmv promoter driven gene expression and may explain somewhat increased gene 
expression of naked pDNA in non-ischemic muscle of MHLIM. It is important to point out 
in this regard that the pDNA/Pluronic expression in normal muscles was shown to be 
promoter selective and dependent on the NF-kB signaling pathway (8, 64). Moreover, 
systemic inflammation caused by ischemia resulted in increased number of circulatory 
MØs, which is consistent with previous studies (65, 66). This may result in increased MØs 
recruitment at the site of pDNA injection due to inflammatory response triggered by 
physical injury and exposure to bacterial CpG motif and ultimately increase muscle 
transfection with pDNA/Pluronic. We also observed increased transgene expression in 
draining lymph nodes, which was in agreement with our earlier studies using i.m. 
pDNA/Pluronic suggesting co-localization of transgene expression with APCs in lymphoid 
organs (16). 
 Altogether, MØs have gained recent attention for their promiscuity or 
plasticity to perform central roles in development, homeostasis and disease and have 
emerged as novel therapeutics target.  Here we resolved a key issue of low muscle 
transfection in ischemic muscles by simple mixing of naked pDNA with Pluronic and 
showed how MØs assist gene transfer to otherwise hard to transfect skeletal muscle 
fibers. Since Pluronics are listed in U.S. Pharmacopoeia and have been demonstrated to 
be safe in clinical trials (67) such formulations have promise for human use.
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CHAPTER 3 
SUPPLEMENTARY DATA 
 
Horizontal Gene Transfer from Macrophages to Ischemic Muscles upon Delivery of 
Naked DNA with Pluronic Block Copolymers  
S3.1.      Supplementary Methods 
S3.1.1.     IHC 
Fresh muscle tissues were embedded in Tissue-Tek OCT (Sakura Finetec Inc, 
Torrance, CA), rapidly cooled to -80oC and sectioned with cryostat microtome. 10 μm thick 
sections were attached to Superfrost® microscope slides (Fisher Scientific, Bellefonte, 
PA), dried for 1 h at RT and stored at -80oC for subsequent use. Double staining 
immunofluorescence was performed in the frozen muscle tissue sections to determine cell 
types expressing GFP. The sections were sequentially treated with (a) polyclonal rabbit 
anti-desmin antibody (Abcam, Cambridge, MA) 1:100, Rat anti-CD11b (eBioscience, San 
Diego, CA) 1:100 antibodies and then (b) with fluorophore-conjugated secondary anti-
species antibodies (Goat anti rat-Alexa 594/Goat anti rabbit-Alexa 633) 1:1000. 
Specifically, frozen sections were incubated at RT for 10-15 min and fixed/permeabilized 
in ice cold methanol for 5 min, followed by ice cold PBS rinse (twice). Slides were 
incubated with 10% normal goat serum in 1x PBS (blocking solution) for 1h at 40C, rinsed 
with PBS (thrice) and incubated with primary antibody in 2% blocking solution o/n at 40C. 
After rinsing with PBS (thrice), the slides were incubated with secondary antibodies in 2% 
blocking solution for 1 h at RT. Finally, the slides were counterstained with DAPI using wet 
mounting system (Vectashield, Burlingame, CA), stored in 40C until examined under 
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microscope. Negative control specimens (treated with secondary antibody alone) were 
used for setting confocal lasers.  
S3.1.2.     ICC.  
The (MØ+DNA)+MB and (MØ+DNA)+MT cocultures were rinsed twice with 
PBS at RT and fixed with fresh 2% formaldehyde solution from 16% stock (TED PELLA, 
Redding, CA) for 20 min at RT. Samples were washed, blocked and labeled with primary 
and secondary antibodies as explained above in IHC. 
S3.1.3.     Confocal Imaging.  
The samples were analyzed by Zeiss 710 Confocal Laser Scanning 
Microscope equipped with a blue diode 405 nm (nucleus), argon laser 488 nm (GFP 
expression), DPSS 594 nm (cell marker) and HeNe 647 nm (cell marker) using 10 x or 20 
x objective. 
S3.1.4.     Exosome isolation.  
Briefly, MØs were transfected using genePORTER300 transfection reagent for 
4 h in SFM and cells were rinsed (twice) with HBSS to remove any pDNA transfection 
reagent. Cells were grown in exosome free CM for another 24 h and 72 h and supernatant 
was collected and exosome isolated by ultracentrifugation method as described in (1). 
S3.2.     Supplementary Discussion 
Since some studies provide evidence for role of extracellular vesicles 
(microvesicles and exosomes) in cell-to-cell communication and DNA exchange (2-4), we 
also studied that possibility behind the pDNA exchange mechanism. MBs and MTs were 
incubated with exosomes, (isolated from pDNA transfected MØ 24 h and 72 h post 
transfection), with and without 1% P85 but the resulting levels of gene expression were 
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below the detection limits (data not shown). We believe, that exosomes at 24 h or 72 h 
represents a snapshot of vesicles. Infact, a more gradual exchange of exosomes from 
pDNA from MØ to MT may explain the horizontal exchange of DNA resulting in muscle 
specific increase in gene expression.  
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Figure S3.1. Stepwise surgical procedure and characterization of inflammation 
model (MHLIM). (a) Animals were anesthetized and surgical removal of artery and vein 
was performed as shown in (b –left) on right leg. (b) Anatomical and histological 
representation of ischemic hind limb muscle tissues and sections. Skin and fascia were 
removed to show the right hind limb muscles of Balb/c mice and the sites of ligation during 
surgical procedure. Hind limb ischemia was generated by excision of FA before femoral 
bifurcation (between sutures marked 1 and 2) and excision of both saphenous artery and 
saphenous vein (between sutures 2 and 3). TA, G, Q and A: designate different muscles 
analyzed. H&E stained 5µm tissue sections of healthy muscles (top row) and ischemic 
muscles at 14th day post ischemia surgery (bottom row) show histopathology of ischemia 
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with a typical inflammatory response (cellular infiltrate) during an inflammation. Tissue 
sections were imaged using 10x objective magnification and images are representative of 
5 slides per tissue and 3 animals per group. Consistent with previous reports (1), the effect 
of ischemia was more pronounced on lower hind limb muscles (TA and G) compared to 
upper hind limb muscles (Q and A). Similar result was obtained H&E sections of ischemic 
muscles at 3rd day post ischemia surgery (not shown). 
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Figure S3.2. Kinetics of gene expression. Representative in vivo images (IVIS 200) for 
healthy and MHLIM mouse after a single injection of 10 µg naked pDNA (gWIZ-Luc, 1st 
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and 2nd row) and pDNA formulated with 0.1% w/v SP1017 (3rd and 4th row) in 50 µl HBSS 
solution. The experiment was carried out in quadruplicate for each treatment group and 
quantified as presented in main text Fig. 1e. 
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Figure S3.3. GFP expression and colocalization with cellular markers. (a, b) 
Colocalization of GFP expression with muscle (a) and MØ (b) markers visualized in 
longitudinal sections of ischemic TA muscles 4 days after gWIZTM GFP injections. The 
color staining corresponds to nucleus (blue); MØs (CD11b+; red); myocytes (desmin+; red); 
and GFP (green). The last panels in each row present digitally superimposed images of 
preceding panels to visualize the colocalization (yellow). The images were taken with Zeiss 
710 confocal laser scanning microscope using 20x objective, scale bar 50µm. 
  
 
 
Figure S3.4. GFP expression through ischemic muscle tissue. Tile scanning confocal microscope images (10 x) of 20 µm 
thick cross-sections at every 500 µm throughout the whole TA muscle tissue 4 days after injections of gWIZTM GFP pDNA alone 
9
5
 
9
6
 
  
 
or pDNA with 0.6 % w/v P85 in ischemic muscles in MHLIM. Representative images from each treatment group with n = 3 are 
shown. Scale bar = 1mm. 
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Figure S3.5. Spread of GFP expression in ischemic muscles. 4 days after pDNA 
injections in ischemic muscles, the spread of GFP expression in 20 µm thick longitudinal 
tissue section was visualized by tile scanning using confocal imaging (10 x). Scale bar = 
1mm. The muscle specimens were harvested after injection and individually processed 
for IHC. Whole muscle longitudinal sections were imaged by confocal tile scanning to view 
the overall GFP expression. Pictures are representative of 3 slides per group.  
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Figure S3.6. Effect of Pluronic on pDNA uptake in various cell types in vitro. RAW 
264.7 MØ, C2C12 MBs and C2C12 derived D7 MTs (50,000 cells/well in 96 well plates, 
24 h after plating) cells were exposed to YOYO-1 labeled gWIZTM Luc pDNA (0.25 µg and 
1 µg) in absence (white bars) or presence of 1% w/v P85 (black bars) in SFM for 2 h. After 
that cells were rinsed thrice with PBS and lysed using 50 μl M-PER® cell lysis reagent 
(ThermoFisher Scientific, Vernon Hills, IL) for 5-10 min at 4 0C. Total fluorescence was 
quantified in cell lysates using Spectramax M5 plate reader (Molecular devices, 
Sunnyvale, CA) at λ Ex/Em 490/591.  Data are mean ± SEM (n=6) *p<0.05, n.s. – non 
significant. 
.     
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Figure S3.7. Effect of skeletal muscle ischemia on transgene expression in 
contralateral muscles. As per scheme in Fig. 6b the test articles were injected in TA 
muscles in healthy mice or in contralateral TA muscles simultaneously with the ipsilateral 
ischemia surgery in MHLIM. Luciferase gene expression in the (a) TA muscles and (b) 
draining lymph nodes of MHLIM (black) and healthy mice (white) was determined 3 days 
after single administration of 10 µg gWIZ™ Luc with or without 2.25% w/v SP1017. pDNA 
injections were performed in TA muscle of healthy mice (white bars) and healthy or non-
ischemic muscles of MHLIM (black bars). Data are mean ± SEM (n = 10), n.s. – non 
significant. Statistical comparisons were made between MHLIM and healthy mice. 
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Figure S3.8. Effect of Pluronic on pDNA uptake in various cell types in vitro. RAW 
264.7 MØ, C2C12 MBs and C2C12 derived D7 MTs (50,000 cells/well in 96 well plates, 
24 h after plating) cells were exposed to YOYO-1 labeled gWIZTM Luc pDNA (0.25 µg and 
1 µg) in absence (white bars) or presence of 1% w/v P85 (black bars) in SFM for 2 h. After 
that cells were rinsed thrice with PBS and lysed using 50 μl M-PER® cell lysis reagent 
(ThermoFisher Scientific, Vernon Hills, IL) for 5-10 min at 4 0C. Total fluorescence was 
quantified in cell lysates using Spectramax M5 plate reader (Molecular devices, 
Sunnyvale, CA) at λ Ex/Em 490/591.  Data are mean ± SEM (n=6) *p<0.05, n.s. – non 
significant. 
.     
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Figure S3.9.  Effect of Pluronic on total gene expression and protein levels in the 
transfected MØs and their co-culture with muscle cells. (a) pDRIVE5Lucia-mDesmin 
transfected MØs were plated alone ([MØ+DNA]), or cocultured on top of the monolayer of 
MBs ([MØ+DNA]+MB) or MTs ([MØ+DNA]+MT). After 2 h, when MØs attach to the MBs 
or MTs, the groups were treated with increasing concentrations of P85 (0.01, 0.1, 0.3 and 
1.0 % w/v) or fresh media for 2 h, washed, further incubated. The total secreted luciferase 
expression was analyzed after 24 h in cell culture media. Total protein content was 
determined in cell lysates after 24 h for (b) [MØ+DNA], (c) ([MØ+DNA]+MB and (d) 
MØ+DNA]+MT groups with and without P85 treatment. Data are mean ± SEM (n=6), 
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Statistical comparisons were made for treated vs. untreated groups. * p<0.05, ** p<0.005, 
n.s. – non significant. 
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Figure S3.10. Cytotoxicity of P85 on MØs (a), MBs (b) and terminally differentiated 
MTs (c) was determined after exposure of the cells to different concentrations of P85 
(0.01%, 0.3% and 1.0%) for different durations (2, 4, 6, and 8 h) in SFM. Cells were further 
cultured for total 24 h if fresh media and the percent cell proliferation, i.e. treated cells 
compared to untreated controls, was determined by MTS assay. Data are mean ± SEM 
(n=6); statistical comparisons were made for P85 treated and untreated groups: * p < 0.05, 
n.s. – non significant. At all-time points examined the proliferation of MØs exposed to lower 
concentrations of P85 (0.01% w/v) was significantly increased compared to untreated 
controls. Likewise MØs exposed to higher concentrations of P85 (0.3 and 1.0% w/v) for 2 
h exhibited greater proliferation compared to untreated controls. However, at longer 
exposures (4, 6 and 8 h) these relatively high concentrations of P85 induced cytotoxic 
effect in MØs. Exposure of MBs to P85 at higher concentrations of (0.3 and 1.0% w/v) 
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induced some limited cytotoxicity. MTs were the most resistant cells with respect to P85 
as no toxicity was observed at any concentration of P85 at any time point studied.
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Figure S3.11. Effect of Pluronic on total gene expression and protein levels in the 
transfected MØs and their co-culture with muscle cells. (a) gWIZ™ Luc pDNA 
transfected MØs were plated alone, [MØ+DNA], or cocultured on top of the monolayer of 
MBs, [MØ+DNA]+MB, or MTs, [MØ+DNA]+MT. After 2 h, when MØs attach to the MBs or 
MTs, the groups were treated with increasing concentrations of P85 (0.01, 0.1, 0.3 and 
1.0 % w/v) or fresh media for 2 h, washed, further incubated. The total luciferase 
expression analyzed after 24 h in cell lysates. Total protein content was determined in cell 
lysates after 24 h for (b) [MØ+DNA], (c) [MØ+DNA]+MB and (d) MØ+DNA]+MT groups 
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with and without P85 treatment. Data are mean ± SEM (n=6), Statistical comparisons were 
made for treated vs. untreated groups. * p<0.05, ** p<0.005, n.s. – non significant. 
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Figure S3.12. Effect of P85 on horizontal gene transfer from transfected MØs to 
muscle cells upon co-culture. (a, b) gWIZ™ Luc pDNA transfected MØs were plated 
alone, [MØ+DNA], or cocultured with MBs, [MØ+DNA]+MB,  or MTs, [MØ+DNA]+MT, and 
exposed to P85 (0.01, 0.1, 0.3 and 1.0 % (b) or 1 % w/v (c)) for 2 h. The total luciferase 
in cell lysates was determined (a) daily for 10 days or (b) after 24 h and normalized for the 
cell protein. A significant decrease in gene expression in [MØ+DNA] v.s. [MØ+DNA]+P85 
groups at day 1 can be explained by detachment of freshly plated MØs upon 1% P85 
treatment, which also explains the decrease in gene expression in upon treatment with 
increasing concentration of P85. (a, b) Data represents mean ± SEM, * p<0.05, n.s. – non 
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significant, (a) (n=12), statistical comparisons were done for coculture with and without 
P85 treatment vs. MØ+DNA groups alone and the curves were compared using AUC and 
one-way ANOVA analysis (b) (n=6). (c) GFP expression (green) in desmin+ MTs (cyan) 
was validated 3 days after their coculture with MØs CD11b+ (red) transfected with gWIZ™ 
GFP pDNA. The last panels in each row present digitally superimposed images (20 x) of 
preceding panels to visualize the co-localization (yellow). Scale bar = 50 µm.
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Figure S3.13. Relative transfection efficiencies in MØ, MB and MT in vitro. Terminally 
differentiated C2C12 derived MT, precursor C2C12 MB and RAW264.7 MØ were 
transfected with gWIZ™ Luc (cmv-luciferase) using genePORTER300 and gene 
expression was determined in cell lysates after 24 h. Data are mean ± SEM (n=4); 
statistical significance was calculated using student’s t test at p<0.05. MTs in general were 
the most difficult to transfect cells. The transfection of these cells using cmv- and desmin-
luciferase pDNA as 90 and 40 times less respectively compared to their precursor MBs 
cells. Consistent with the literature MØs were in general more difficult to transfect cells 
than undifferentiated proliferating cells (MBs).  
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Figure S3.14. Effect of Pluronic block copolymers on the gene expression in RAW 
264.7 MØs. Cells were exposed to gWIZ-Luc pDNA with or without P85 in SFM for 2 h 
using 1 µg pDNA and various concentrations of P85 and replaced with CM. After 24 h, 
luciferase gene expression in 10 µl cell lysates was quantified using Glomax20/20 
luminometer with an integration period of 10 s. Data are mean ± SEM (n=4). 
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Figure S3.15. Bio-distribution of RAW264.7 Macrophages loaded with alexa fluor-
680 labeled nanozyme in healthy and MHLIM.  5X106 MØ/200ul PBS were injected via 
intra jugular in healthy (A) and ischemic (B) of mice, 48 hours post ischemia surgery (Day 
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0). Representative images of n=3 per group showed no trafficking of unpolarized 
macrophages to ischemic tissues unless polarized with MCSF for 48 h.  
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CHAPTER 4 
Harnessing Macrophages Response to Increase Gene Delivery to Muscle Using 
pDNA Formulated with Pluronic Block Copolymers 
ABSTRACT 
Previously Pluronic block copolymers were shown to drastically increase the 
level and duration of reporter gene expression after intramuscular (i.m.) administration of 
plasmid DNA (pDNA) in immunocompetent animals. This was not seen in athymic nude 
mice. Therefore, this study explores possible involvement of innate immune response in 
Pluronic enhanced gene transfer. After intraperitoneal (i.p.) administration of gWIZ™Luc 
plasmid DNA (pDNA), formulated with Pluronic P85 (P85) there was a profound increase 
in the peritoneal exudate cells (PECs) characterized by enhanced recruitment of anti-
inflammatory monocytes (MOs) and neutrophils in euthymic Balb/c, but not in the athymic 
nude mice. The anti-inflammatory MOs response in Balb/c mice was observed to both 
pDNA/P85 and P85 copolymer alone and peaked about 1 day after their administration. 
This was very different from responses to conventional adjuvants such as alum and 
lipopolysaccharide (LPS) that increased PECs in both mouse strains (except for LPS in 
Balb/c), and enhanced recruitment of neutrophils, while having relatively little or no effect 
on anti-inflammatory MOs. In contrast to P85 neither alum nor LPS increased pDNA 
expression in the muscle of Balb/c mice. The depletion of MOs / macrophages (MØs) in 
Balb/c mice by clodronate-liposomes resulted in abolishment of P85 enhanced pDNA 
expression, which reinforced the role of these cells in the muscle transfection. To increase 
MOs / MØs recruitment the muscles were pre-injected with P85 1.5 days prior to 
subsequent pDNA/P85 injections in the same muscles. This strategy resulted in further 
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significant enhancement of the muscle transfection. Overall, the results suggest that by 
harnessing the MOs / MØs responses using Pluronic block copolymers one can enhance 
the gene transfer to the muscle using pDNA. 
4.1.       Introduction 
The transfection of the skeletal muscle after direct intramuscular (i.m.) injection 
of naked plasmid DNA (pDNA) was discovered in 1990s by John Wolf and coworkers (1). 
Since then this simple methodology has been used in numerous clinical trials (2, 3). 
However, development of a successful gene therapy on its basis has been hindered due 
to low levels and short duration of gene expression after i.m. injections of naked pDNA. 
Therefore, improvements of the muscle transfection efficiency have been actively sought 
for nearly quarter of century (4-10). Early on it became obvious that conventional non-viral 
transfection approaches involving condensation of pDNA with cationic lipids or polymers 
that have been developed for in vitro gene delivery are not applicable for direct i.m injection 
(11, 12). Incorporation of pDNA in lipoplexes or polyplexes instead of increasing gene 
expression in the muscle abolished it in comparison to the naked pDNA.  
In contrast, some progress in gene delivery to the muscle was achieved with 
physical methods in combination with pDNA, such as electroporation that produces limited 
injury to the muscle and increases gene expression (13, 14). The electroporation-
mediated gene transfer (EGT) involves application of electric current that generates 
transient aqueous pores in the membranes of muscle cells and induces electrophoretic 
movement and entry of pDNA through these pores (12, 15). The electrical injury also 
results in intensification of recruitment of immune response cells (16, 17) in particular 
CD11b+ cells (18), which may affect gene expression. 
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Another, successful approach reported by us and others involves co-
administration of pDNA with Pluronics (poloxamers), a series of nonionic block copolymers 
that do not condense pDNA but nevertheless drastically increase the level and duration of 
gene expression in the muscle (19-21). The efficiency of this method is comparable with 
that of EGT (20). Moreover, pDNA/Pluonic formulation applied in combination with EGT 
results in further increase in gene expression in the muscle compared to the naked pDNA 
with EGT (22). This effect was previously explained by ability of Pluronic to facilitate 
sealing of the electroporation-damaged membranes and increase survival of the 
transfected cells (23).  
However, until recently the mechanism of gene delivery using pDNA/Pluronic 
formulations was not entirely clear. Kabanov’s group has discovered that Pluronics can 
increase gene transfer in the cells in vitro using pDNA-condensed polyplexes 
(pDNA/polycation interpolyelectrolyte complexes) (24-26). They explained this by 
increased intracellular uptake of pDNA, enhanced translocation of pDNA to the nucleus 
and activation of transcription of the delivered gene (24-26).The two latter processes 
appeared to correlate with the ability of Pluronic to activate NF-κB signaling in the cells 
and the presence of NF-κB response elements in the pDNA, suggesting that the 
copolymer can engage innate mechanisms for cellular transport and processing of pDNA 
(21, 26). Similar factors may actually contribute to the pDNA gene expression in the 
muscle since the effect of Pluronic on pDNA expression in the muscle strongly depends 
on the presence of the NF-κB in the promoter region of the plasmid (21).  
In the meantime it became clear that the muscle transfection is a complex 
process that involves multiple cells types and depends on specific and non-specific 
immune responses initiated by the needle tissue damage, presence of CpG sequences in 
pDNA backbone and the expression of the encoded protein (27-29). Additionally, the 
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immune response cells such as macrophages (MØs) can capture pDNA in the cytoplasmic 
vesicles and express transgenes not only in the injected muscles but also in the distal 
lymphoid organs (30, 31). It is generally believed that immune responses can negate the 
gene expression of pDNA in the nucleus by inducing premature silencing of episomal 
pDNA due to methylation of the CMV promoter (16, 27-29, 32). Moreover, a specific 
cytotoxic T-lymphocyte response against antigen expressed by the transfected muscle 
fibers can also damage host tissue and thereby further decrease gene expression (33). 
Therefore, inflammatory responses have been generally visualized as an adverse factor 
for a successful gene delivery (16, 27-29, 32, 33). 
We did report, however, that Pluronic effect on gene expression in the muscle 
was strain-dependent (absent in immunodeficient athymic nude mice) suggesting strong 
correlation of immune response and gene expression enhancement (21). Moreover, 
following i.m. administration of pDNA/Pluronic formulation in euthymic mice the levels of 
DNA, RNA and encoded protein were greatly increased in draining lymph nodes and 
spleen, where the expressed protein co-localized with MØs and dendritic cells (34). Most 
recently we demonstrated that the in vitro transfected MØs can horizontally transfer the 
transgene in vitro to the new host cells and after adoptive transfer to animal models carry 
the transgenes to the distal sites of inflammation (35, 36). Therefore, we hypothesize that 
monocytes (MOs) and MØs can participate in the Pluronic enhanced gene transfer of the 
naked pDNA to the muscle. To test this hypothesis in this paper we 1) examined the effect 
of Pluronic on MOs recruitment in healthy euthymic and athymic mice; 2) depleted 
MOs/MØs in euthymic mice and examined the effect of the depletion on the Pluronic 
enhanced pDNA expression in the muscle, and 3) attempted to boost MOs recruitment by 
Pluronic pre-injections followed by i.m administration of pDNA/Pluronic formulation to 
further increase gene expression in the muscle. The results suggest that 1) the innate 
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immune responses and in particular recruitment of MOs/MØs play essential role in 
Pluronic enhanced gene expression and 2) MOs/MØs can be harnessed to further 
increase i.m. expression of pDNA/Pluronic formulations. 
4.2.       Material and Methods 
4.2.1.       Plasmids 
The gWIZ™ high expression vector encoding the reporter genes, luciferase 
(gWIZ™ Luc) under control of an optimized human cytomegalovirus (CMV) promoter 
followed by intron A from the CMV immediate-early gene (Genlantis, San Diego, CA) was 
used for i.m. injections throughout the study. All plasmids were expanded in E. coli DH5α 
host and purified using endotoxin-free Qiagen Plasmid Giga Kit (Qiagen, Valencia, CA) 
according to the supplier’s protocol. Final pDNA pellet was reconstituted in endotoxin free 
Dulbecco’s phosphate buffered saline (DPBS) and characterized by restriction 
endonuclease digestion followed by agarose gel electrophoresis. pDNA was stored at -
20oC until use. Plasmid solution endotoxin levels quantified using 
ToxinSensorTM Chromogenic LAL Endotoxin Assay Kit were negligible (13E U/mg the FDA 
allowed limit ≤40EU/mg pDNA). 
4.2.2.       Animals 
All animal experiments were carried out with approval of the University of 
Nebraska Medical Center (UNMC) and University of North Carolina at Chapel Hill (UNC-
CH) Institutional Animal Care and Use Committee (IACUC) and in accordance with the 
NIH Guide for Laboratory Animal Use. Female Balb/c or female athymic nu/nu (Charles 
River Laboratories, Wilmington, MA) mice of 6 to 8 weeks age were used throughout this 
study. The animals were kept in groups of five and fed ad libitum.  
4.2.3. pDNA/Pluronic formulations and i.m. injections 
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Pluronic L61 (batch # WPNT-511B), P85 (batch # WPNT-511B), F127 (batch 
# WPNT-511B) were a kind gift from BASF Co. (Mount Olive, NJ). The pDNA formulations 
were prepared as described (34) and used immediately for i.m. injections using 1 c.c. 
insulin syringes. Specifically, mice were anesthetized using ketamine and xylazine mixture 
(100 mg/kg and 5 mg/kg respectively) and pDNA/Pluronic mixtures were injected in tibialis 
anterior (TA) muscle as 50 µl sterile solution. Injections were performed with needle 
direction parallel to TA muscle and a flow rate of 0.6-0.7 ml/min. In select experiments 
P85 at a given concentration alone was injected in TA muscle followed by injection of 
naked pDNA alone or pDNA/0.3% or 0.6% P85 in the same TA after 1.5 day or 5 days.  
The sample of SP1017 used in this work by V.M. behaved very different 
compared to SP1017 samples previously described in literature and other laboratories. In 
particular SP1017 as tested was not increasing pDNA expression in the muscle as was 
previously documented by many investigators. We suspect that the components used for 
preparation of this sample were subjected to chemical degradation. Unfortunately, prior to 
completion of this dissertation we were not able to obtain new sample of SP1017 and 
therefore present the results obtained with the old samples with understanding that in the 
future our laboratory will carry out studies as the new sample is available. 
4.2.4.       Tissue Histology 
In one experiment the TA muscles were injected with P85 (0.3% w/v, 3% w/v 
and 10% w/v) and then either 1.5 or 5 days after injections removed en bloc and processed 
as described earlier (14). Five µm thick, 3 sections per muscle were processed for 
Hematoxylin & Eosin (HE) staining. In another experiment, the spleen tissues from 
MO/MØ depleted and normal mice were isolated en bloc, embedded using Tissue-Tek 
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O.C.T. compound and frozen at -800C. 10 µm thick sections were stained with F4/80+ 
antibody-HRP conjugate (Clone BM8; ebiosciences, San Diego, CA) followed by 
HIGHDEF red IHC chromogen staining as per supplier’s recommendation (Enzo Life 
Sciences, Farmingdale, NY). 
4.2.5.       Luciferase gene expression 
Unless indicated otherwise mice were euthanized at the indicated time points 
in the figure legends and tissues were processed as described in (34). The luciferase gene 
expression in 10 µl tissue homogenates was quantified using Glomax 20/20 luminometer 
(Promega, Fitchburg, WI) for an integration period of 10 s respectively as described before 
(34). Alternatively, luciferase activity in live animals was measured for the indicated time 
using in vivo imaging system IVIS-200 (Xenogen Corporation, Alameda, CA) 5 min after 
i.p injection of D-luciferin and the imaging data were quantified as described before using 
1 min integration time (34). The signal intensity was quantified as the sum of the 
photons/sec/cm2/sr detected and the results were analyzed using Living Image® v2.50 
software. 
4.2.6.       Peritoneal lavage and multi-color flow cytometry 
Each euthymic Balb/c and athymic nude mouse was injected intraperitoneally 
(i.p.) with 250 µl of DPBS, 50 µg naked pDNA alone, 0.3% w/v P85/pDNA, 0.01% w/v 
SP1017/pDNA, 25 µg lipopolysaccharide (LPS) (Sigma-Aldrich, St. Louis, MO) or 500 µg 
alum (2% Alhydrogel; InvivoGen, San Diego, CA). All mice were sacrificed by cervical 
dislocation at the indicated time points and the peritoneal cavities were lavaged with cold 
3 ml RPMI media (without phenol red) supplemented with 10% fetal bovine serum using 
25G needle, massaged for 1 min and cells extracted using 22 G needle. The procedure 
was repeated thrice. Finally, peritoneal cavity was opened to collect any residual fluid and 
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a total ~9 ml peritoneal exudate cells (PECs) were centrifuged at 500 g for 10 min, washed 
twice with DPBS, and resuspended in 100 µl 1x FACS buffer (BD Biosciences, San Jose, 
CA). Cell viability was determined by trypan blue exclusion test using Countess® 
automated cell counter (Life Technologies, Grand Island, NY) before processing the cells 
for flow cytometry. 106 live cells in 100 µl 1x FACS buffer were treated with Mouse BD Fc 
BlockTM (Rat anti-mouse CD16/CD32), washed twice with 100 µl DPBS and stained with 
LIVE/DEAD fixable violet stain (Life Technologies, Grand Island, NY) as per supplier’s 
recommendations. Excess LIVE/DEAD stain was removed by washing cells twice with 100 
µl DPBS and finally resuspended in 50 µl 1x FACS buffer. The PECs were then mixed 
with 50 µl mixture of various fluorescently labeled monoclonal antibodies against murine 
cell surface markers (Supplementary Tables S1, S2) and incubated for 30 min at 40C in 
dark. Finally, after washing the cells in cold 1x FACS buffer, stained samples were fixed 
with BD stabilizing fixative, filtered using 35 µm nylon mesh and kept in the dark at 40C 
until data was acquired using LSR-II flow cytometer (Becton Dickinson, San Jose, CA) at 
UNC flow cytometry core facility (within 24 h of surface labeling). Data was acquired with 
Forward (FSC) and side (SSC) scatter on a linear scale, while fluorescent signals were 
collected on a 4-decade log scale with a minimum of 50,000 events per sample. Flow 
samples were compensated with single color compensation data collected using AbCTM 
anti-mouse bead kit (Life Technologies, Grand Island, NY) and the frequency distribution 
of different cells types (MOs and neutrophils) was determined by applying gates derived 
from the FMO (fluorescence minus one) controls on cells. Finally, the data analysis was 
performed using FlowJo_V10 (FLOWJO LLC, Ashland, OR). 
4.2.7.       In vivo MØs/MOs depletion 
MØ/MO depletion protocol using clodronate-liposomes was adopted from a 
previous study (37). Specifically, 200 µl clodronate- or clodronate free-liposome 
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(Encapsula NanoScience LLC, Brentwood, TN) were injected twice via lateral tail vein 
injections either a) 20 or 2 h before or b) on and 18 h after pDNA injections. According to 
the manufacturer the liposomes were composed of L-alpha-phosphatidylcholine (5mg/ml) 
and cholesterol (18.8 mg/ml) with and without clodronate (5mg/ml) suspended in DPBS 
saline at pH 7.4. In each administration scheme, luciferase gene expression was analyzed 
in tissue homogenates 24 h after pDNA injections. 
4.2.8.       Statistical analysis 
Student’s t-test was used to calculate statistical differences between groups at 
p < 0.05 in all in vitro and in vivo experiments unless indicated otherwise. 
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4.3. Results 
4.3.1. PEC responses to pDNA/Pluronic, LPS and Alum in immunocompetent 
and nude mice 
Previously, we reported that Pluronics increase muscle transfection of naked 
pDNA in immunocompetent (euthymic C57Bl/6 and Balb/c) but not in immunodeficient 
(athymic nude) mice (21). To better understand the strain-dependency of muscle 
transfection, we compared the immune responses in euthymic Balb/c and athymic nude 
mice to pDNA alone and pDNA formulated with copolymers (pDNA/P85 and 
pDNA/SP1017). Along with the pDNA and pDNA/Pluronic groups the treatment groups 
also included mice administered with alum or LPS to illicit a conventional adjuvant (alum) 
and non-specific pathogen-derived inflammatory (LPS) responses. A standard peritoneal 
lavage assay was used for immunological profiling of innate immune cells in different 
treatment groups as explained in (38, 39). In Balb/c mice the pDNA and pDNA/P85 
injections increased PEC counts by ~2- and ~6-fold respectively, while pDNA/SP1017 
injections did not produce significant changes compared to DPBS controls (Fig. 4.1a). In 
contrast, in nude mice changes in PEC were not significant in pDNA- or any of the 
pDNA/Pluronic groups. On the contrary, alum- and LPS that considerable responses in 
both in Balb/c and nude mice. Interestingly, the responses to alum and LPS in the nude 
mice were even greater than those in Balb/c mice (~7 and ~8 times vs. ~4 and ~1.4 times, 
respectively). 
Next we delineated the MOs response. It was reported that upon co-
administration with pDNA in the muscle P85 increases expression of the transgene in 
distal lymphoid organs, such as draining lymph nodes and spleen, where the transgene 
co-localizes with antigen presenting cells (APCs), specifically dendritic cells and MØs (34). 
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Moreover, our recent work implicated MØs in the horizontal gene transfer to muscle 
(submitted) and brain cells (35, 36) during inflammation. Therefore total PECs were 
labeled with antibodies against cell surface markers to characterize the MOs recruitment. 
Flow cytometric dot plots showed that all treatment groups except for LPS displayed 
recruitment of mainly anti-inflammatory MOs (M2-MOs, SSCint-hiFSCint-
hiCD11b+Ly6GloF4/80lo/intLy6Clo). However, LPS recruited both inflammatory MOs (M1-
MOs, SSCint-hiFSCint-hiCD11b+Ly6GloF4/80lo/intLy6Chi) and anti-inflammatory M2-MOs in 
both euthymic and athymic mice (red and black arrows in Fig. 4.1b and gating scheme in 
Supplementary Fig. S4.1). Still the MOs recruitment by alum or LPS in athymic mice was 
relatively small and the considerable spikes in the overall PEC counts in these groups 
(Fig. 4.1a) were explained by the recruitment of other cell types. In particular, there was 
an increase in the percent (and total counts) of neutrophils both in alum and LPS treated 
athymic mice to 73% and 50% compared to only 2% and 10 % M2-MOs in each of these 
groups, respectively (Supplementary Fig. S4.2). 
Of all the compositions pDNA/P85 elicited the greatest and significant increase 
in both frequency (~5 times) and counts (~27 times) of M2-MOs compared to DPBS control 
in the Balb/c mice (Fig. 4.1c, d). The M2-MOs counts in this group were also significantly 
higher than those in pDNA alone group (~13 times) suggesting a strong adjuvant effect of 
P85 resulting in recruitment of M2-MOs. This effect was only observed in euthymic Balb/c 
mice and was attenuated in nude mice where the recruitment of M2-MOs in response to 
pDNA/P85 was much less than that in Balb/c mice. Still it remained significantly higher 
than the recruitment of M2-MOs in pDNA alone and DPBS control groups. Interestingly, 
in these two groups in nude mice the levels of M2-MOs have also shown a tendency to 
decrease compared to the respective groups in Balb/c mice. 
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Along with the M2-MOs pDNA/P85 also elicited recruitment of neutrophils in 
Balb/c mice (Supplementary Fig. S4.2). But in contrast to alum and LPS the neutrophils 
response in athymic mice treated with pDNA/P85 was low and significantly less than that 
in euthymic mice. Interestingly, a considerable increase in the T-lymphocyte recruitment 
was also observed in euthymic Balb/c after pDNA/P85 injection (Supplementary Fig. 
S4.3).  
Finally, we studied the kinetics of Pluronic-induced MOs recruitment. In this 
case along with the pDNA alone and pDNA formulated with copolymers the treatment 
groups also included the copolymers alone. Both P85 and pDNA/P85 produced a 
considerable increase in M2-MOs frequency and total counts compared to DPBS control 
or pDNA, which peaked at 24 h after i.p. administration (Supplementary Fig. S4.4). 
Interestingly, at this time point the response to P85 alone was even higher than that to 
pDNA/P85 i.e. vs. 5.3 x106 vs. 3.5x106 total M2-MOs counts. The MOs recruitment 
response subsided by day 5 or 10 post injection (Supplementary Fig. S4.4). In this 
experiment neither SP1017 nor pDNA/SP1017 increased MOs recruitment compared to 
DPBS or pDNA groups. Therefore, in subsequent experiments we focused only on 
formulations containing P85.
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Figure 4.1. Innate immune response to adjuvant formulations quantified using peritoneal 
lavage. The panels present (a) total PEC response, (b) qualitative dot plots, (c) frequency (%) and 
(d) total numbers of peritoneal M2-MOs in Balb/c (white) and nude (black) mice. Each mouse was 
injected i.p. with 250 µl of the following solutions: saline (DPBS), 50 µg naked pDNA, 50 µg 
pDNA/0.3% P85, 50 µg pDNA/0.01% SP1017, 500 µg Alum or 25 µg LPS. The PECs were isolated 
24 h after injections by the lavage procedure and (a) counted or (b-d) processed for flow-cytometry. 
(b) The inflammatory (SSCint-hiFSCint-hiCD11b+Ly6GloF4/80lo/intLy6Chi) and anti-inflammatory 
(SSCint-hiFSCint-hiCD11b+Ly6GloF4/80lo/intLy6Clo) MOs are marked by red and black arrows, 
respectively (Gating scheme shown in Supplementary Fig. S1). (a, c, d). Data are mean ± SEM of 
n = 3 to 6. Statistical comparisons were made between treatment group and DPBS control for each 
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mouse strain (# Balb/c, #p<0.05 and @ nude, @p<0.05) and between treatment groups of different 
or same strain (*p<0.05). In all cases n.s. stands for non-significant
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4.3.2. In vivo MOs and MØs depletion abolishes Pluronic-induced increase in 
muscle transfection 
Intravenous (i.v.) clodronate-liposomes have been used to deplete MOs in 
circulation, as well as MØs in liver and spleen (40). The maximum depletion of circulatory 
MOs is observed ~18 h to 24 h post administration of clodronate-liposomes. In this work 
to elucidate the role of circulatory MOs in gene transfer we used two doses of clodronate-
liposomes administered in two different schedules: either a) prior to or b) on and after 
pDNA injections (Fig. 4.2a, b). The control groups were injected with DPBS as well as 
empty liposomes of the same composition. The transgene expression in the muscle was 
quantified 24 h after pDNA injections. 
In the first schedule pDNA/P85 displayed significant increase in gene 
expression compared to naked pDNA in DPBS or empty liposomes groups, but not in 
clodronate-liposome groups where there was a trend for an increase (Fig. 4.2c). The gene 
expression with pDNA/P85 in this latter group was attenuated compared to animals 
pretreated with empty liposomes suggesting that MOs depletion inhibited gene delivery 
with pDNA/P85. (Interestingly, empty liposomes boosted transgene expression compared 
to DPBS controls in pDNA/P85 but not the naked pDNA groups.) 
In the second schedule clodronate-liposome produced even more pronounced 
decrease in the gene expression of pDNA/P85 compared to both DPBS and empty 
liposome treated animals (Fig. 4.2d). This scheme probably provided a better timing for 
the MOs depletion, since the recruitment of anti-inflammatory MOs by pDNA/P85 
injections (which takes about 24 h, see Supplementary Fig. S4.4) was probably offset by 
MOs depletion due to the second injection of the clodronate-liposomes. Notably the 
clodronate-liposomes treatment led to a nearly complete reversal of gene expression of 
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pDNA/P85 to the naked pDNA levels. No decrease in gene expression was observed in 
naked pDNA groups, suggesting that MOs play a much lesser role in the muscle 
transfection with the naked pDNA. Our interpretations were further confirmed by the 
analysis of the spleen sections suggesting that MØs depletion was greater in mice treated 
with clodronate-liposome on and after pDNA/P85 injection compared to those treated with 
clodronate-liposome before pDNA injections (Fig. 4.2e). 
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Figure 4.2. Effect of in vivo MOs and MØs depletion on muscle transfection. (a-d) MOs/MØs 
were depleted by i.v. administration of clodronate-liposomes (two injections of 0.2 ml 
liposome/mouse) either (a, c) before (scheme 1) or (b, d) on/after (scheme 2) pDNA administration. 
The mice injected with DPBS or clodronate free liposomes are shown for comparison. In all test 
groups 10 µg / 50 µl naked gWIZTM Luc pDNA and pDNA/P85 were injected in left TA muscle and 
luciferase gene expression was quantified in muscle tissue homogenates after 24 h. Data represent 
means ± SEM, n = 5, and was analyzed using Student’s t-test at *p<0.05. In all cases n.s. stands 
for non-significant. (e) Immunohistochemical staining of F4/80 MØ marker (red) on frozen spleen 
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sections obtained from mice injected i.v. with DPBS, PBS-liposome or Clodronate liposome in 
scheme 1 and scheme 2, 24 h after pDNA/P85 injection. Scale bar=200 µm.
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4.3.3. Effects of Alum and LPS on muscle transfection with pDNA 
Since LPS was shown to increase MOs frequency in both euthymic and 
athymic mice, while alum did not have such effects in any of the strains we compared the 
effects of Alum and LPS on the pDNA expression with that of P85. In this study pDNA or 
pDNA/P85, LPS or alum were injected into TA muscles and the transgene expression was 
quantified as described above. As expected and published earlier, pDNA/P85 failed to 
increase transfection of the muscles in nude mice compared to the naked pDNA (21). In 
addition, we did not observe any increase in transgene expression using pDNA/LPS or 
pDNA/alum instead of the naked pDNA (Fig. 4.3). In fact, the transgene expression after 
administering pDNA/alum was 10 and 68 times lower than that of the naked pDNA in 
Balb/c and nude mice, respectively. This could be explained by decreased muscle 
transfection upon condensation of naked pDNA by cationic alum (41) and strong alum-
induced neutrophil infiltration response (73% of total cells) resulting in muscle damage 
(42). Moreover, pDNA/LPS did not increase transgene expression in either Balb/c or nude 
mice. This suggests that either MOs recruitment by LPS is not sufficient to achieve the 
desired effect or both MOs recruitment and co-delivery of P85 with pDNA are necessary 
to produce high transgene expression. 
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Figure 4.3. Differential effects of P85, Alum and LPS on muscle transfection. 10 µg / 50 µl 
gWIZTM Luc pDNA alone or formulated with adjuvants (0.3% P85, 5 µg LPS and 100 µg Alum) were 
injected in TA muscle of euthymic Balb/c and athymic nude mice. Gene expression analysis 24 h 
after DNA injection demonstrated a strain- and adjuvant-dependent effect on muscle transfection. 
Data represents mean ± SEM of n = 5 and statistical significance was calculated by using student’s 
t-test at *p<0.05. In all cases n.s. stands for non-significant.
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4.3.4. Preinjection of P85 further increases muscle transfection levels 
After determining that MOs and P85 have mutually inclusive role in assisting 
gene transfer of pDNA in the muscle we evaluated whether MOs can be harnessed to 
further increase the transgene expression. To this end we examined the cell recruitment 
in the TA muscles injected with P85 (0.3%, 3% and 10% w/v) by tissue histology. There 
was a typical cellular recruitment response characterized by purple hematoxylin nuclear 
staining in the muscle tissue along with the weak pink eosin staining suggesting tissue 
regeneration on day 1.5 after injection of the copolymer (Fig. 4.4a). This response 
subsided on day 5 in 0.3% and 3% P85 groups (Supplementary Fig. S4.5a). However, at 
higher concentration of 10% P85 the muscle injury was beyond repair resulting in 
excessive cellular recruitment and necrosis.  
To synergize MOs recruitment response with the pDNA delivery we first injected 
P85 in the TA muscles, and then after 1.5 days (right after the peak MOs recruitment) 
administered pDNA/P85 to the same muscles (Fig. 4.4b). The time course of luciferase 
gene expression was quantified by IVIS imaging (Supplementary information Fig. S4.6). 
The results suggested that preinjection of P85 affects the transgene expression in a 
concentration dependent fashion (Fig. 4.4c-e). Specifically, the 0.3% P85 injected 1.5 
days before pDNA/P85 did not change the peak expression on day 10 but considerably 
prolonged the transgene expression for nearly 60 days compared to expression in 
pDNA/P85 groups without preinjection that faded after 20 days (Fig. 4.4d-e). The 3% P85 
increased the peak gene expression on day 10 by ~2.5 and ~16 times compared to 
pDNA/P85 and pDNA without the preinjection (Fig. 4.4c,d). Interestingly, preinjection of 
3% P85 also showed some effect on expression of naked pDNA (Supplementary Fig. 
S4.7). The highest concentration of the copolymer (10% P85), which produced sustained 
muscle injury and necrosis decreased the gene expression level of pDNA/P85. In a 
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parallel experiment, we administered pDNA/P85 5 days after P85 injection when the MOs 
recruitment response subsided (Fig. S4.4b). This had either negative or no effect on the 
transgene expression (Figs. S4.4c-e). Only with 0.3% P85 preinjection some prolongation 
of gene expression was observed similar to the effect observed at the same dose with 
short preinjection schedule. 
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Figure 4.4. Effect of Pluronic preinjection 1.5 days before before administration of pDNA/P85 
on the gene expression in the muscle. (a) Muscle histology (H&E staining) at 1.5 days after P85 
preinjection. (Left) Longitudinal sections (2x and 10x) showed a typical inflammatory cellular 
infiltrate (purple; hematoxylin nuclear staining) accompanied by muscle regeneration (light pink; 
weak eosin staining). (Right) Representative images of freshly isolated muscles en bloc of n = 3. 
(b) Scheme of the experiment involving preinjection of TA muscles with P85 (0.3%, 3% and 10%) 
followed 1.5 days after that by injection of 10 µg pDNA/0.3% P85. (c-e) Luciferase expression at 
different time points after pDNA or pDNA/P85 injections quantified by IVIS imaging 5 min after i.p 
injection of D-luciferin: (c) time course (d) Day 10 and (e) Day 40. Data represents mean ± SEM, 
n = 3. Statistical comparisons were made between naked pDNA alone (without P85 preinjection) 
and pDNA/P85 groups (with and without preinjection), *p<0.05, n.s. stands for non-significant.
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4.4. Discussion 
Coordinated sequence of leukocyte recruitment is the hallmark of innate 
immune response (43-45). Adjuvants intensify and modulate the leukocyte infiltrate 
(magnitude, quality and kinetics) resulting in a specific adaptive immune response (38). 
Accordingly, adjuvants that assist in cell mediated or humoral immune response are 
defined as Th1 (e.g., dimethyldioctadecylammonium liposomes with monophosphoryl 
lipid-A or DDA/MPL) and Th2 (e.g., Aluminium hydroxide or Al(OH)3), respectively. 
Development of new customized adjuvants capable of recruiting specific cell populations 
is a promising strategy to elicit a unique adaptive immune response (38) or other 
downstream effects such as muscle transfection.  
Pluronic block copolymers have gained considerable interest as adjuvants in 
protein (46, 47) and DNA based vaccination approaches (48, 49). Their effects on 
immunity are known to involve both Th1 and Th2 signaling (50). We and others have 
shown that they can also act as very potent enhancers of gene expression in the muscle 
(19-21) and that their effect on gene expression is mediated by the APCs, that can carry 
the gene from the site of injection in the muscle to spleen and distal lymph nodes (34). 
Moreover, previously published data suggested that Pluronics do not enhance muscle 
transfection in immunedeficient athymic nude mice (21, 51), which implied a mutually 
inclusive role of both immune cells and copolymers in the muscle transfection.  
In this study we conducted profiling of the innate immune responses to 
pDNA/Pluronic and compared them with the responses to common adjuvants, alum and 
LPS. This study resulted in two important findings. The first finding was the different 
responses to pDNA/Pluronic observed in euthymic Balb/c and athymic nude mice. 
Specifically, pDNA/P85 in euthymic Balb/c mice greatly increased the recruitment of M2-
MOs, as well as neutrophils and T-cells at 24 h after administration of pDNA/P85. In 
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contrast, in athymic nude mice that lack a normally developed T-cell system the 
recruitment of M2-MOs and neutrophils was attenuated, suggesting T-cell dependence of 
the response. Since T cells may enhance the innate immune cell recruitment at the site of 
pDNA injection (52), T cell absence in nude mice is likely to explain the loss of MOs and 
neutrophils recruitment in pDNA/P85 injected nude mice.  
The second finding was the very different profiles of the responses to 
pDNA/Pluronic compared to alum and LPS. Although the alum and LPS appeared to 
somewhat increase the recruitment of M2-MOs in Balb/c mice, their effect was marginal 
compared to that of pDNA/P85. Most importantly the major component in the responses 
to these compositions in Balb/c mice was the neutrophil recruitment. And these responses 
in contrast to pDNA/Pluronic were not attenuated but rather increased in the nude mice. 
The latter finding was consistent to earlier studies, which reported an abnormally high 
“compensatory” neutrophil infiltration in nude mice resulting in their protection against 
otherwise lethal bacterial and fungal infections (53, 54). Our results suggested that 
pDNA/P85 was recognized by a mechanism different than pathogen recognition and the 
T-cell system dependent recruitment of MOs was a major difference compared to the 
common adjuvants. 
Interestingly, pDNA co-formulated with alum or LPS did not show any increase 
in the gene expression in TA muscle compared to the naked pDNA. We speculate that 
this might be due to the lack of the MOs response. Some grounds for this speculation was 
already contained in our previous publications. In particular, we reported co-localization of 
expressed genes with MØs as well as dendritic cell markers in muscle, spleen and lymph 
nodes, along with the increased systemic and local expansion of the MØs, dendritic cell 
and natural killers after i.m. injection of pDNA/P85 (34). We also reported the co-culture 
experiments demonstrating horizontal gene transfer from in vitro transfected MOs/MØs to 
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brain cells (35, 36) and most recently to muscle cells (submitted). Finally, we 
demonstrated that the transfected MOs/MØs can be adoptively transferred to a mouse 
model and carry the gene to the site of injury and inflammation where this gene is 
expressed (35, 36). In this study we directly demonstrate that the depletion of MOs/MØs 
essentially abolished the effect of Pluronic on pDNA expression in the muscle. We 
speculate that the needle injury upon injection produces the inflammation response and 
MOs/MØs infiltration in the muscle (16), where the MOs/MØs capture the pDNA and 
promote transfection. The copolymer, which does not bind or interact with pDNA (21), 
boosts the innate immune response and recruitment of MOs as described above, thereby 
enhancing the MOs/MØs dependent gene transfer to the surrounding cells. The initiation 
of innate immune response in the muscle is still being investigated. Reports question the 
possibility of resident MØs during steady state in muscle parenchyma and instead showed 
MØs in muscle epimysium (connective tissue surrounding muscle tissue) and perimysium 
(connective tissue surrounding muscle fibers), where they may help orchestrate the initial 
immune recognition recruiting more cells from the nearby blood vessels (55, 56). Since 
the block copolymer enhancement of muscle transfection appears to be dependent on 
innate immune response, additional MOs recruitment can be triggered by resident MØs in 
epimysium and perimysium. 
In this case the proper timing of recruitment of the MOs could be a very 
important factor in gene transfer. Since the copolymer alone was shown to activate the 
MOs recruitment 24 h after i.m. injection the pre-injections of the copolymer can be used 
to harness the MOs to the sites of subsequent pDNA injections resulting in further 
improvement of muscle transfection. Specifically, the level of gene expression was greatly 
increased when the muscle was preinjected with P85 followed by administering 
pDNA/P85. Interestingly, the peak levels as well as the duration of the gene expression 
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depended on the concentration of the copolymer in the preinjection solution as well as in 
the pDNA/P85 formulation. The timing of preinjection was also critical as the separation 
of the copolymer and pDNA/P85 by 5 days when the MOs recruitment subsided did not 
result in the increased gene expression. Therefore, by optimizing the copolymer doses as 
well as the treatment time schedule one can possibly fine-tune the immune response and 
the gene expression profiles, which can result in interesting opportunities in gene delivery 
strategies. 
4.5. Conclusions 
Gene therapy approaches based on i.m. injection of naked pDNA are hindered 
by low and transient gene expression of the pDNA in the muscle. Pluronic block 
copolymers co-injected with the pDNA have been shown to increase the level and duration 
of the gene expression thereby potentially expanding the use such approaches. This study 
provides a new mechanistic insight in the effect of Pluronics, using P85 as example. The 
findings strongly suggest that the copolymer activates the innate immune response, in 
particular recruitment of M2-MOs, which is instrumental in assisting Pluronic/DNA 
transfection. This is the first report that demonstrates that 1) by depleting MOs/MØs the 
effects of P85 were abolished and 2) by harnessing MOs/MØs response prior to 
administration of pDNA/P85 the muscle tissue transfection can be further enhanced. 
These findings are of significant theoretical and practical interest and can be used to 
further optimize the use of Pluronics in i.m. gene delivery applications. 
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CHAPTER 4 
SUPPLIMENTARY DATA 
Harnessing Macrophage Response to Increase Gene Delivery to Muscle Using 
pDNA Formulated With Pluronic Block Copolymers 
 
Table S4.1. Fluorescently labeled monoclonal antibodies used for cell surface staining of PEC. 
Panel for MOs and 
Neutrophils 
Excitation  
(nm) 
Emission 
 (nm) 
Amount used 
(µg/106 cells) 
Rat Anti-Mouse CD11b-
APC-Cy7 
650 785 0.25 µg 
Rat anti-mouse Ly-6C-APC 650 660 0.25 µg 
Rat Anti-Mouse Ly-6G PE-
Cy7 
496 667 0.25 µg 
Rat Anti Mouse F4/80 PE 496 578 0.25 µg 
 
Table S4.2. Fluorescently labeled monoclonal antibodies used for cell surface staining of lymphoid 
cells. 
Panel for T cells Excitation  
(nm) 
Emission 
 (nm) 
Amount used 
(µg/106 cells) 
Rat Anti-Mouse CD19b-PE 650 785 0.25 µg 
Rat Anti-Mouse CD45-PE-
Cy7 
496 667 0.25 µg 
Hamster Anti-Mouse CD3e-
PE 
496 578 0.25 µg 
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S4.1.        Materials and Methods 
S4.1.1.     TLR screening  
P85 solutions were made fresh and shipped overnight to InvivoGen 
laboratories (InvivoGen, San Diego, CA) to test TLR binding to P85 on individual TLR 
expressing HEK cells. Seven different HEK cell lines stably transfected with individual 
mTLR (2, 3, 4, 5, 7, 8 and 9) along with secreted alkaline phosphatase reporter gene under 
the control of NF-kB inducible promoter were incubated with P85 (0.1% and 1%) and 
positive controls (TLR2: HKLM (Heat killed listeria monocytogenes) at 108 cells/ml, TLR3: 
poly (I:C) at 1ug/ml, TLR4: E.Coli K12 LPS at 100ng/ml, TLR7: CL097 at 1ug/ml, TLR8: 
CL075 at 10ug/ml+Poly(dT) at 10uM, TLR9: CpG ODN 1826 at 1ug/ml) for 16-20 h in a 
96 well plate. The activity of P85 solutions were tested at 1/10 of stock conc. (10% and 
1%) by adding 20ul of sample in 180 µl of media and TLR activation was quantified by 
measuring secreted alkaline phosphatase (SEAP) activity in cell culture media using 
QUANTI-Blue substrate and colorimetric detection of SEAP product at 622-655 nm using 
spectramax (Molecular Devices, Sunnyvale, CA).  
 
S4.1.2.      Endotoxin assay 
The ToxinSensorTM Chromogenic LAL Endotoxin Assay Kit (GenScript, 
Piscataway, NJ) was used to detect endotoxin levels in formulations as per supplier‘s 
recommendation. The observed levels were negligible (same as endotoxin free DPBS) 
and 13EU/mg respectively which were less than the FDA allowed limit (≤40EU/mg pDNA).
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Figure S4.1. Gating strategy used for discriminating MOs (SSCint-hiFSCint-
hiCD11b+Ly6GloF4/80lo/intLy6Clo/hi) and neutrophil (SSCint-hiFSCint-hiCD11b+F4/80int-
loLy6Ghi) from total PECs. Debris and lymphocytes (SSC-A vs. FSC-A) and doublets 
(FSC-H vs. FSC-A) were excluded. Live/dead cells were determined using the amine 
reactive fixable violet stain. CD11b+ myeloid lineage cells were subgated on SSCint-
hiFSCint-hiCD11b+Ly6GloF4/80lo/intLy6Clo/hi MOs by excluding CD11b-, F4/80hi (MØs) and 
Ly6Ghi (Neutrophil) cells. 
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Figure S4.2. Neutrophil (Neu) recruitment induced by alum and LPS in athymic mice 
resulted in spike in PEC response. Each euthymic Balb/c (open bars) and athymic nude 
(solid bars) mouse was injected i.p. with 250 µl of DPBS, 50 µg naked pDNA alone, 50 µg 
pDNA/0.3% P85, 50 µg pDNA/0.01% SP1017, 500 µg Alum or 25 µg LPS. The PEC’s 
were isolated 24 h later by lavage procedure and processed for flow-cytometry. (a, b) 
Peritoneal neutrophils were characterized as SSCint-hiFSCint-hiCD11b+F4/80int-loLy6Ghicells 
in lavage fluids of Balb/c (white) and nude (black) mice (Gating scheme shown in Fig. S1). 
Data represent means ± SEM of n = 3 to 6. Statistical comparisons were made between 
treatment group and DPBS control for each mouse strain (# Balb/c, #p<0.05 and @ nude, 
@p<0.05) and between treatment groups of different or same strain, *p<0.05. In all cases 
n.s. stands for non-significant.
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Figure S4.3. Effect of Pluronic and pDNA/Pluronic on the recruitment of T cells 
(CD45+CD19-CD3e+) in the euthymic mice. Balb/c mice were injected i.p. with 250 µl of 
DPBS, 0.3% P85, 0.01% SP1017 alone or these solutions containing 50 µg pDNA. PECs 
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were isolated at various time points (day 1, day 5 and day 10) and labeled with respective 
cell surface markers to identify CD45+CD19-Cd3e+ T cells and analyzed by FlowJo. (Left) 
T cells frequency (%) and (Right) total T cells are presented. Data are mean ± SEM of n 
= 3. Statistical comparisons between groups were done using student’s t-test at *p<0.05. 
In all cases n.s. stands for non-significant. 
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Figure S4.4. Time course of the Pluronic induced M2-MOs recruitment in euthymic 
mice. Balb/c mice were injected i.p. with 250 µl of DPBS, 0.3% P85, 0.01% SP1017 alone 
or mixed with 50 µg pDNA. PECs were isolated at various time points (day 1, day 5 and 
day 10) and labeled with respective cell surface markers to characterize and quantify (a, 
b) % M2-MOs frequency (%) and (c, d) total M2-MOs by flow cytometry. Data represent 
means ± SEM of n = 3 and statistical significance was calculated by using student’s t-test 
at *p<0.05. In all cases n.s. stands for non-significant. 
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Figure S4.5. Effect of Pluronic preinjection 5 days before administration of 
pDNA/P85 on the gene expression in the muscle. (a) Muscle histology (H&E staining) 
at 1.5 days after P85 preinjection. (Left) Longitudinal sections (2x and 10x) showed no 
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cellular recruitment at 0.3% and 3% but tissue necrosis at 10% P85 injection. (Right) 
Representative images of freshly isolated muscles en bloc of n = 3. (b) Scheme of the 
experiment involving preinjection of TA muscles with P85 (0.3%, 3% and 10%) followed 5 
days after that by injection of 10 µg pDNA/0.3% P85. (c-e) Luciferase expression at 
different time points after pDNA or pDNA/P85 injections quantified by IVIS imaging 5 min 
after i.p injection of D-luciferin: (c) time course (d) Day 10 and (e) Day 40. Data represents 
mean ± SEM, n = 3. Statistical comparisons were made between naked pDNA alone 
(without P85 preinjection) and pDNA/P85 groups (with and without preinjection), *p<0.05, 
n.s. stands for non-significant. 
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Figure S4.6. Day 1.5 and Day 5 Preinjection imaging. Representative ventral images 
of the transgene expression in Balb/c mice taken at different time points after i.m. 
injections of 10 µg gWIZ-Luc pDNA without or with 0.3% P85 in 50 µl DPBS. In select 
experiments (a) 1.5 days or (b) 5 days before gene transfer the animals were preinjected 
in the same muscles P85 solutions of different concentrations (0.3%, 3 % and 10 %) of 
P85 in 50 µl DPBS. Luciferase gene expression was quantified by IVIS imaging 5 min after 
i.p injection of D-luciferin substrate.  
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Figure S4.7. Effect of P85 preinjection 1.5 days before administration of naked 
pDNA, pDNA/0.3% P85 or pDNA/0.6% P85 on the gene expression in the muscle. 
Bilateral TA muscles were first injected with 50 µl P85 solution (0.3 %, 1.0 % and 3.0 %) 
and then after 1.5 days with 50 µl formulation of 10 µg naked pDNA, pDNA/0.3% P85 or 
pDNA/0.6% P85. Luciferase gene expression was quantified in tissue homogenates 4 
days after gene transfer. Data represent mean ± SEM (n=6-8). Statistical comparisons: * 
p<0.05; n.s. stands for non-significant.  
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Figure S4.8. Effect of the size of needle injury on pDNA/P85 gene transfer. (a) 18 G 
metallic needles were trimmed to appropriate size to make two different sized collars that 
exposed only 3 mm or 6 mm (including bevel length of ca. ~1mm) of 25 G needle tip during 
i.m. injections. (b) Gene expression in muscles injected 3mm and 6mm deep were 
compared with muscles injected with pDNA and pDNA/0.3% P85 without needle collars. 
The gene expression increased inversely with needle depth, marginally higher levels in 3 
mm deep, intermediate levels in randomly deep and marginally lower in 6 mm deep 
injections. Data represents mean ± SEM of n = 5 and statistical comparisons were made 
between pDNA/P85 and pDNA alone using student’s t-test at * p<0.05. 
162 
 
 
 
 
 
(
a) 
(
b) 
(a) 
(b) 
163 
 
 
 
Figure S4.9. Pluronic do not activate Toll Like Receptors (TLR’s). Pluronic P85 
(0.01% and 1.0% w/v) and control ligand were exposed to each stably transfected HEK-
293 cell line with a given mouse TLR (a) and NFKB negative control HEK-293 cells (b) for 
16-20 h and tested for reporter gene expression by Molecular Devices Spectramax340PC. 
Data are mean ± SEM (n=3). 
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CHAPTER 5 
OVERALL CONCLUSIONS, SIGNIFICANCE AND FUTURE DIRECTIONS 
In this dissertation work, we used a pragmatic approach to understand the key 
questions related to gene delivery in skeletal muscles. Direct i.m. injection of naked pDNA 
to transfect skeletal muscles for the purpose of therapeutic protein expression is a well-
established approach in preclinical and clinical studies. We were the first to show that 
muscle transfection can be further enhanced upon co-injection of non-ionic block 
copolymer with pDNA. However, this effect is strain-dependent and not observed in 
immune-deficient athymic mice. Also, coadministration of block copolymer with pDNA 
resulted in enhanced transgene expression not only in injected muscles but also in 
draining lymph nodes and spleen. Therefore, we studied the role of immune cells in gene 
transfer and gene expression. The current work examined 1) the role of inflammation 
and inflammatory cells, specifically, MØs on gene transfer upon delivery of naked 
DNA with pluronic block copolymers; 2) the immunological profiling of innate 
immune response against pDNA/copolymer to identify key cells involved in gene 
transfer and evaluate the potential of engineering the immune response to further 
enhance muscle transfection of pDNA/copolymer.  
 
In chapter 3 we investigated the effects of local inflammation in murine hind 
limb ischemia model (MHLIM) on gene expression and found that inflammation drastically 
increased DNA, RNA and protein levels in muscles injected with pDNA/Pluronic. Ischemic 
muscles showed high number of GFP+ muscle fibers with GFP expression co-localized 
with desmin+ muscle fibers and CD11b+ MØs. This suggested that Pluronic assist muscle 
transfection through MØs. Therefore, using in vitro cell culture model we showed that P85 
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enhanced (~4 orders) transfection of MØs with naked pDNA. Moreover, adoptively 
transferred DNA transfected MØs were shown to traffic to the sites of inflammation and 
pass the transgenes to inflamed muscle cells. We observed a clear colocalization of 
CD11b marker along the sides of desmin suggesting cell-to-cell contact dependent 
exchange of genes from MØs to muscle cells. However, we cannot rule out the possibility 
of other immune cell recruitment to ischemia muscles like neutrophils contributing to the 
colocalization of CD11b+ with desmin. Nevertheless, we observed a significant 
colocalization of GFP with CD11b confirming that transfected MØs homed to the ischemic 
muscles.  
Therefore, we developed an in vitro model by co-culturing transfected MØs 
with MTs and used constitutive (cmv-luciferase) or muscle specific (desmin-luciferase) 
reporter gene expression to show that P85 enhances horizontal pDNA transfer from MØ 
to MTs. This study was particularly interesting because it recapitulated inflammatory 
microenvironment similar to in vivo setting. Also, we understand that the concentrations 
of Pluronic treatment in coculture was around 3.3 times higher (1% w/v) than used for i.m. 
injection (0.3% w/v), but we limited our treatment to only 2 h duration which is relatively 
very short duration of treatment to observe drastic increase in muscle specific gene 
expression. Finally, significant increase in transgene expression was seen upon systemic 
inflammation (MHLIM or peritonitis) with pDNA/Pluronic but not pDNA alone. The findings 
of this chapter indicate that MØs present in inflammation play a significant role in muscle 
transfection with pDNA/Pluronic by assisting horizontal exchange of pDNA. We conclude 
that pDNA/Pluronic has potential for therapeutic gene delivery in muscle pathologies that 
involve inflammation. 
In this study we propose that in pluronic gene delivery approach, MØs can 
uptake the pDNA and as a part of evolutionary process of regeneration, can fuse with 
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muscle fibers resulting in gene delivery to other wise hard to transfect skeletal muscles 
(discussed in chapter 3 and shown in Fig. 2.2). However, the frequency of MØ to muscle 
fusion is very low (<0.1%) and Pluronic may enhance these events as a function of PEG 
motifs (Poly-ethylene oxide). Therefore a follow-up study may require analysis of MØ to 
muscle cell fusion with and without Pluronic treatment using live imaging to quantify the 
absolute effect. 
In chapter 4, we carefully dissected innate immune response to the naked 
pDNA alone or when formulated with Pluronic. Immunophenotyping of the PECs from both 
euthymic Balb/c and athymic nude mice showed that P85 evokes a response unlike 
pathogen recognition response of bacterially derived LPS. Specifically, each adjuvant 
(alum/LPS/P85) helped recruit a characteristic PEC response which was both qualitatively 
and quantitatively different in Balb/c mice. The overall response further increased in 
athymic nude mice in response to LPS/alum, but an opposite effect was observed to P85. 
Increase in PEC response in P85 Balb/c and LPS/alum nude group was composed majorly 
of MØs and neutrophils, respectively. These results suggested that P85 induced MØ 
recruitment may explain the reason for increase in gene expression upon i.m. injection of 
pDNA/Pluronic in healthy mice. This effect was confirmed when pDNA/P85 was unable to 
transfect MØ depleted Balb/c mice upon pDNA/P85 injection. These results confirmed that 
lack of MØ recruitment in nude mice was the reason for strain-dependent response in 
pDNA/P85.  Moreover, we applied this knowledge to engineer a MØ recruitment response 
to the subsequent site of pDNA/P85 injection to further increase the muscle transfection. 
Specifically, pre-injection with P85 1.5 day prior to subsequent pDNA/P85 injections in the 
same muscles resulted in further improvement in pDNA/P85 muscle transfection. We 
understand that preinjection with P85 induced an inflammatory response, which can be a 
concern, however a detailed pathological and histological examination can help optimize 
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the scheme based on the disease pathology under investigation. Furthermore, gene 
expression with of pDNA/P85 was inversely correlated with the depth of needle injection, 
suggesting that survival of muscle fibers along the needle track may be critical for gene 
delivery in healthy muscles. 
It was striking that Pluronic, alum and LPS adjuvants did not evoke a typical 
inflammatory response but rather a very specific cellular recruitment composed of different 
proportions of MØs and neutrophils. Since Pluronic resulted in a response different from 
alum/LPS both qualitatively and quantitatively, it can be used to design a custom adjuvant 
formulation to modulate immune responses in a specific and controlled manner. 
Therefore, we believe that more immunological profiling studies can help derive structure 
function relationships amongst a range of Pluronics aimed at designing “smart adjuvants” 
for gene and protein delivery applications. 
During the studies, many open ended questions arose that need to be 
addressed carefully. Specifically, activation of NF-kB and other inflammatory signaling by 
Pluronic can be a concern for gene delivery applications in diseased muscles with chronic 
inflammation e.g. muscular dystrophy where the aim is to rescue muscle death. Also, there 
is a direct correlation of hydrophobicity or adjuvancy of pluronic with muscle transfection 
efficiency (L61>P85>F127) which might raise similar concerns. Also, there is a dose 
dependent response of Pluronic on muscle transfection with a typical bell shaped curve 
for each Pluronic with an optimal concentration. This could be explained by membrane 
damage to the transfected muscle fiber beyond repair after a certain concentration 
(optimal) resulting in eventual decrease in muscle transfection. However, we still did not 
understand the rationale for the right shift in the bell shaped curve in ischemic muscle 
compared to healthy muscles resulting in increased optimal concentrations of both P85 
and SP1017. 
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 Overall, we thoroughly investigated the effects of Pluronic on gene 
expression using various in vitro and in vivo models. 
 
Future directions. 
We showed that Pluronic block copolymers enhance gene transfer from MØ to 
muscle cells is a pragmatic approach. However, it will be interesting to study the effects 
of Pluronic on muscle regeneration. A body of evidence in EGT and regenerative medicine 
suggests that Pluronics (Poloxamer 188) help reduce the traumatic injury caused by 
electric pulses during EGT (1) and also help regeneration in wound healing. Specifically, 
we observed an increase in desmin expression when MBs were cocultured with MØ, this 
may imply a MØ dependent satellite cell maturation to form new muscle cells. Since 
Pluronic modulates cellular recruitment to MØ predominated response, this may further 
enhance the differentiation of precursor muscle cells in to muscle fibers. Alternatively, 
since Pluronic may assist MØ to muscle cell fusion as explained in our proposed model of 
gene transfer (Fig 2.2), this response may also enhance overall muscle regeneration. 
Pre-injection scheme for improved muscle transfection results in artificial 
APCs/MØ recruitment which can potentially intensify the antigen presentation in muscle 
and draining lymph nodes in otherwise non-immunogenic nature of DNA vaccines. It will 
be very interesting to utilize this scheme (pDNA/P85 injection 1.5 day after 3% P85 
preinjection) and compare it to pDNA/P85 and naked pDNA alone to evaluate a potential 
prophylactic or therapeutic efficacy in a relevant disease mouse model. 
Drastic increase in transgene expression in pDNA/P85 in response to local or 
distal inflammation can be very effective regime to enhance the gene expression levels in 
human clinical trials specifically because most of the disease pathologies often involve 
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inflammation. Currently upto 2.4 mg of pDNA of the course (Neovasculogen; plasmid 
genetic construction containing human gene VEGF165) (2) is injected in the patients 
suffering from lower limb ischemia in Phase –III clinical trials for achieving enough VEGF 
expression for therapeutic efficacy. With pDNA/Pluronic approach, there is great potential 
to decrease the potential amount of pDNA required for same or even enhanced protein 
expression and simultaneously decreasing the potential inflammatory response caused 
by high dose of pDNA injections (3). 
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